var title_f27_51_28464="TSB guideline phototherapy";
var content_f27_51_28464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Guidelines for phototherapy in hospitalized infants of 35 or more weeks gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use total bilirubin. Do not subtract direct reacting or conjugated bilirubin. Risk factors include isoimmune hemolytic diseases, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin &lt;3.0 g/dL (if measured). For well infants 35-37 6/7 wk can adjust TSB levels for intervention around the medium risk line. It is an option to intervene at lower TSB levels for infants closer to 35 wks and at higher TSB levels for those closer to 37 6/7 wk. It is an option to provide conventional phototherapy in hospital or at home at TSB levels 2-3 mg/dL (35-50 mmol/L) below those shown but home phototherapy should not be used in any infant with risk factors. Note: These guidelines are based on limited evidence and the levels shown are approximations. The guidelines refer to the use of intensive phototherapy which should be used when the TSB exceeds the line indicated for each category. Infants are designated as \"higher risk\" because of the potential negative effects of the conditions listed on albumin binding of bilirubin, the blood-brain barrier, and the susceptibility of the brain cells to damage by bilirubin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Subcommittee on Hyperbilirubinemia. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2004; 114:297. Copyright &copy; 2004 The American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28464=[""].join("\n");
var outline_f27_51_28464=null;
var title_f27_51_28465="Eye anatomy PI";
var content_f27_51_28465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Common eye disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vision loss can be caused by different problems in the eye:",
"    <br>",
"     <ul>",
"      <li>",
"       Presbyopia makes it hard for the lens to focus",
"      </li>",
"      <li>",
"       Cataracts make the lens cloudy",
"      </li>",
"      <li>",
"       Glaucoma damages the optic nerve",
"      </li>",
"      <li>",
"       Macular degeneration damages the macula, the part of the eye that allows you to see fine detail",
"      </li>",
"      <li>",
"       Diabetic retinopathy damages the blood vessels in the retina, the part of the eye that receives visual images and sends these images to the brain",
"      </li>",
"     </ul>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28465=[""].join("\n");
var outline_f27_51_28465=null;
var title_f27_51_28466="Phases of perinatally acquired hepatitis B virus infection";
var content_f27_51_28466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Phases of perinatally acquired hepatitis B virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 662px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HBV: hepatitis B virus; IU: international units; ALT: alanine aminotrasferase; AFP: alpha fetoprotein.",
"     <br>",
"      * All patients with hepatitis B virus (HBV) infection should have baseline assessment for risk of hepatocellular carcinoma (HCC), and follow up monitoring. We generally monitor AFP and liver ultrasound every 12 months beginning in late childhood. For patients with elevated AFP, cirrhosis, or a family history of hepatocellular carcinoma, we begin monitoring earlier and monitor more closely.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28466=[""].join("\n");
var outline_f27_51_28466=null;
var title_f27_51_28467="Benign prostatic hyperplasia (BPH)";
var content_f27_51_28467=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/51/28467/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28467/contributors\" id=\"au3645\">",
"       Glenn R Cunningham, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28467/contributors\" id=\"au3603\">",
"       Dov Kadmon, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/51/28467/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28467/contributors\" id=\"se158\">",
"       Michael P O'Leary, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/51/28467/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28467/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/51/28467?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BPH OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Benign prostatic hyperplasia is a condition that occurs when the prostate enlarges, potentially slowing or blocking the urine stream. Other names for benign prostatic hyperplasia include benign prostatic hypertrophy, an enlarged prostate, and BPH. BPH occurs only in men; approximately 8 percent of men aged 31 to 40 have BPH. In men over age 80, more than 80 percent have BPH.",
"    </p>",
"    <p>",
"     Many men with BPH have no symptoms. In men with symptoms, the most common include needing to urinate frequently (during the day and night), a weak urine stream, and leaking or dribbling of urine. These symptoms are called lower urinary tract symptoms (LUTS). For men with bothersome symptoms, treatment with one or more medicines or surgery is available.",
"    </p>",
"    <p>",
"     More detailed information about BPH is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"      \"Medical treatment of benign prostatic hyperplasia\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"      \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE PROSTATE GLAND",
"     </span>",
"    </p>",
"    <p>",
"     The prostate is a small gland that is part of the male reproductive system. It sits just below the bladder and in front of the rectum (",
"     <a class=\"graphic graphic_figure graphicRef65675 \" href=\"UTD.htm?36/32/37382\">",
"      figure 1",
"     </a>",
"     ). The prostate is normally about the size of a walnut.",
"    </p>",
"    <p>",
"     The prostate is composed of two lobes, covered by an outer layer of tissue. The prostate surrounds the urethra, the tube that carries urine from the bladder through the penis and outside the body.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BENIGN PROSTATIC HYPERPLASIA CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     It is not clear why some men develop symptoms of BPH or lower urinary tract symptoms (LUTS) and others do not. The prostate normally enlarges to some degree in all men with advancing age, although not all men require treatment. Several hormones are required for BPH to develop, but these hormones alone do not cause the condition.",
"    </p>",
"    <p>",
"     Some experts believe that a family history of the condition increases a man's risk of developing BPH. Frequency of sex and having a vasectomy do not increase a man's chances of developing BPH.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      BENIGN PROSTATIC HYPERPLASIA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of BPH usually begin after age 50. The most common symptoms of BPH include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Frequent urination, especially at night",
"      </li>",
"      <li>",
"       A hesitant, interrupted, or weak stream of urine",
"      </li>",
"      <li>",
"       The need to urinate frequently",
"      </li>",
"      <li>",
"       Leaking or dribbling of urine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These symptoms tend to appear over time and may gradually worsen over the years. However, some men have an enlarged prostate that causes few or no symptoms, while other men have symptoms of BPH that later improve or stay the same. Some men are not bothered by their symptoms, while others are bothered a great deal.",
"    </p>",
"    <p>",
"     In a small percentage of men, untreated BPH can cause urinary retention, meaning that the man is unable to empty the bladder. The risk of urinary retention increases with age and as symptoms worsen.",
"    </p>",
"    <p>",
"     Symptoms of BPH can also be caused by other conditions, including prostate or bladder cancer, kidney stones, and overactive bladder. Overactive bladder causes a strong, frequent, uncomfortable need to urinate immediately.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      BENIGN PROSTATIC HYPERPLASIA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     To know if BPH or another problem is causing your symptoms, a doctor or nurse will ask you questions, perform an exam, and do blood and urine tests. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"      \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Rectal exam &mdash; Your doctor or nurse will need to perform a rectal examination to feel the size and shape of the prostate gland. A rectal exam can help to determine if there are signs of prostate cancer (",
"       <a class=\"graphic graphic_figure graphicRef80412 \" href=\"UTD.htm?12/30/12768\">",
"        figure 2",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Urinalysis &mdash; You might be asked for a urine sample to see if you have a bladder infection. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"        \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Blood tests &mdash; A blood test to check the prostate-specific antigen (PSA) level is recommended. PSA is a protein produced by prostate cells; the PSA level may be increased in men with BPH. Men who have prostate cancer often have a highly disproportionately-elevated PSA level, although prostate cancer is also found in men who do not have an elevated PSA.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Having BPH does not increase your risk for prostate cancer. However, it is possible to have both BPH and prostate cancer at the same time. If your PSA test is higher than normal, you will need further testing to be sure that you do not have prostate cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"      \"Patient information: Prostate cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Urodynamic study",
"     </span>",
"     &nbsp;&mdash;&nbsp;A bladder test, known as a urodynamic study, might be recommended for some men who have signs or symptoms of BPH. This test can give information about how well the bladder and urethra are working.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      BENIGN PROSTATIC HYPERPLASIA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatments for BPH can help to reduce urinary symptoms. Treatment options include medicines and surgery.",
"    </p>",
"    <p>",
"     Men with mild BPH might not need treatment. In this case, most experts recommend a \"wait and watch\" approach. This means that you will watch your symptoms over time. In some cases, BPH symptoms improve without treatment. However, men with moderate to severe symptoms usually require treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are two types of medicine used to treat BPH: alpha blockers and alpha-reductase inhibitors. Most men with BPH who start taking a medicine will need to take it forever. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"      \"Medical treatment of benign prostatic hyperplasia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Alpha blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;These medications relax the muscle of the prostate and bladder neck, which allows urine to flow more easily. There are at least four medications in this category: terazosin (Hytrin&reg;), doxazosin (Cardura&reg;), tamsulosin (Flomax&reg;), alfuzosin (Uroxatral&reg;), and silodosin (Rapaflo&reg;). Terazosin and doxazosin were initially developed to treat high blood pressure, but were later found to be useful for men with BPH.",
"    </p>",
"    <p>",
"     Alpha blockers begin to work quickly and are usually recommended as a first-line treatment for men with mild to moderate symptoms.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects &mdash; The most important side effects of alpha blockers are dizziness and low blood pressure after sitting or standing up. Terazosin and doxazosin are usually taken at bedtime (to reduce lightheadedness). The dose can be increased over time if needed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should not take terazosin and doxazosin if you take a medicine for erectile dysfunction (ED), such as sildenafil (Viagra&reg;), vardenafil (Levitra&reg;), and tadalafil (Cialis&reg;). Tamsulosin and alfuzosin usually do not interact with ED medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Alpha-reductase inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alpha-reductase inhibitors are medicines that can stop the prostate from growing further or even cause it to shrink. Finasteride (Proscar&reg;) and dutasteride (Avodart&reg;) are alpha-reductase inhibitors.",
"    </p>",
"    <p>",
"     This type of medicine works better in men with a larger prostate. It can reduce the risk of urinary retention (not being able to empty the bladder) and the need for surgery. Most men see an improvement within six months of starting treatment.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects &mdash; A small percentage of men who take alpha-reductase inhibitors have decreased sex drive or difficulty with erection or ejaculation. Rarely, this problem causes men to stop BPH treatment. This side effect is reversed when the drug is stopped.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     PSA levels decrease by about 50 percent in men who take finasteride or dutasteride. This is important to remember if you have PSA testing to screen for prostate cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"      \"Patient information: Prostate cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Combination treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;A combination of an alpha blocker and an alpha-reductase inhibitor might be recommended for certain men. This may benefit men:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       With severe symptoms",
"      </li>",
"      <li>",
"       With a large prostate",
"      </li>",
"      <li>",
"       Who do not improve with the highest dose of an alpha blocker",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Herbal medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Herbal therapies for BPH, such as saw palmetto, are commonly used in Europe for treatment of BPH. However, the best studies of saw palmetto have shown no benefit in reducing the symptoms of BPH. For this reason, we do not recommend the use of saw palmetto or other herbal medicines to treat BPH. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=see_link\">",
"      \"Clinical use of saw palmetto\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Lifestyle changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;All men with BPH should avoid medicines that can worsen symptoms or cause urinary retention. These include certain antihistamines (such as diphenhydramine [Benadryl&reg;]) and decongestants (eg, pseudoephedrine [found in some cold medicines]).",
"    </p>",
"    <p>",
"     Lifestyle changes are also recommended if you are bothered by having to go to the bathroom frequently. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Stop drinking fluids a few hours before bedtime or going out",
"      </li>",
"      <li>",
"       Avoid or drink less fluids that can make you go more often, like caffeine and alcohol",
"      </li>",
"      <li>",
"       Double void. This means that after you empty your bladder, you wait a moment and try to go again. Do not strain or push to empty.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Surgical treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;If medicines do not relieve your symptoms of BPH, a surgical treatment may be recommended. Surgery is used to reduce to reduce the amount of prostate tissue around the urethra (",
"     <a class=\"graphic graphic_figure graphicRef65675 \" href=\"UTD.htm?36/32/37382\">",
"      figure 1",
"     </a>",
"     ). This may be done by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Removing some prostate tissue",
"      </li>",
"      <li>",
"       Shrinking the prostate with heat",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Each treatment has advantages and disadvantages, and the best treatment depends on the size and location of the excess prostate tissue and your preferences. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"      \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Transurethral resection of the prostate (TURP)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Transurethral resection of the prostate (TURP) is the most common surgical treatment for BPH. The surgeon inserts a device through the urethra to remove strips of the enlarged prostate. The procedure is done while you are asleep and takes 60 to 90 minutes. Most men stay in the hospital overnight after TURP.",
"    </p>",
"    <p>",
"     Serious complications are rare with TURP. The most common complications include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Needing to wear a catheter to empty the bladder temporarily",
"      </li>",
"      <li>",
"       Bleeding for up to several weeks after surgery",
"      </li>",
"      <li>",
"       Injury of the prostate",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     After surgery, most men have less semen with ejaculation because much of the semen is directed into the bladder. However, difficulties with erection and pain with ejaculation often improve after surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Transurethral needle ablation (TUNA)",
"     </span>",
"     &nbsp;&mdash;&nbsp;In this procedure, specific areas of the enlarged prostate are burned away. TUNA can usually be performed using only local anesthesia (usually lidocaine gel, which is inserted into the urethra), and the man is usually able to go home after the procedure. This procedure improves the flow of urine and reduces BPH symptoms.",
"    </p>",
"    <p>",
"     TUNA is often preferred for men with medical problems, particularly men who must take blood-thinning medications like warfarin (Coumadin&reg;). TUNA is also an alternative for men who prefer a procedure that has a lower risk of urine leakage and sexual side effects. However, men treated with TUNA are more likely to need another BPH procedure over time compared with men who have TURP.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Other procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of other surgical procedures are available for men with BPH.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Microwave thermotherapy &mdash; This procedure uses heat to destroy excess prostate tissue. It is performed as a day surgery, and most men are able to go home after the procedure.",
"       <br/>",
"       <br/>",
"       Thermotherapy does not cure BPH or problems emptying the bladder (retention). However, it does improve symptoms of needing to rush to the bathroom frequently, the need to strain, and slow urine flow.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Transurethral incision of the prostate (TIP) &mdash; In this procedure, a surgeon widens the urethra (",
"       <a class=\"graphic graphic_figure graphicRef65675 \" href=\"UTD.htm?36/32/37382\">",
"        figure 1",
"       </a>",
"       ). Prostate tissue is not removed. Transurethral incision of the prostate (TIP) is performed with anesthesia and generally requires a 24-hour stay in the hospital.",
"       <br/>",
"       <br/>",
"       TIP might be recommended for men who cannot empty their bladder and do not have a large prostate, especially if the man has other medical problems. Another surgical treatment for BPH is sometimes needed a few years after TIP.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Removal of the prostate &mdash; Surgery to remove the prostate (prostatectomy) might be recommended for men who are healthy and have a very enlarged prostate.",
"      </li>",
"      <li>",
"       Laser surgery &mdash; With laser surgery, a surgeon uses laser to destroy prostate tissue and shrink the prostate. Laser surgery is similar to a TURP but causes less bleeding.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804583526\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14512300\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/21/15698?source=see_link\">",
"      Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/27/32176?source=see_link\">",
"      Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/11/29873?source=see_link\">",
"      Patient information: Prostatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/9/35987?source=see_link\">",
"      Patient information: Urinary incontinence in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/5/37970?source=see_link\">",
"      Patient information: Hydronephrosis in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14512346\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/55/38770?source=see_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=see_link\">",
"      Clinical use of saw palmetto",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34104?source=see_link\">",
"      Epidemiology and pathogenesis of benign prostatic hyperplasia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/prostatediseases.html\">",
"      www.nlm.nih.gov/medlineplus/prostatediseases.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Urological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.auanet.org/\">",
"      www.auanet.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/index.htm\">",
"      file://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/51/28467/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/51/28467?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28467/abstract/1\">",
"      Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28467/abstract/2\">",
"      Flanigan RC, Reda DJ, Wasson JH, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28467/abstract/3\">",
"      Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28467/abstract/4\">",
"      McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28467/abstract/5\">",
"      Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol 2006; 175:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28467/abstract/6\">",
"      Roehrborn CG. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am 1995; 22:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28467/abstract/7\">",
"      Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004; 94:738.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_51_28467=[""].join("\n");
var outline_f27_51_28467=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BPH OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE PROSTATE GLAND",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BENIGN PROSTATIC HYPERPLASIA CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           BENIGN PROSTATIC HYPERPLASIA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           BENIGN PROSTATIC HYPERPLASIA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           BENIGN PROSTATIC HYPERPLASIA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37382\" title=\"figure 1\">",
"           Prostate anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/30/12768\" title=\"figure 2\">",
"           Rectal exam PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_51_28468="Senna: Patient drug information";
var content_f27_51_28468=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Senna: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40276?source=see_link\">",
"     see \"Senna: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/1/42003?source=see_link\">",
"     see \"Senna: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Black Draught&reg; [OTC];",
"     </li>",
"     <li>",
"      Evac-U-Gen&reg; [OTC];",
"     </li>",
"     <li>",
"      ex-lax&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      ex-lax&reg; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Quick Dissolve [OTC];",
"     </li>",
"     <li>",
"      Fletcher's&reg; [OTC];",
"     </li>",
"     <li>",
"      Geri-kot [OTC];",
"     </li>",
"     <li>",
"      Little Tummys&reg; Laxative [OTC];",
"     </li>",
"     <li>",
"      Perdiem&reg; Overnight Relief [OTC];",
"     </li>",
"     <li>",
"      Senexon&reg; [OTC];",
"     </li>",
"     <li>",
"      Senna-Lax [OTC];",
"     </li>",
"     <li>",
"      SennaGen [OTC];",
"     </li>",
"     <li>",
"      Senokot&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to senna or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, belly pain, upset stomach, rectal bleeding, throwing up, or change in bowel habits lasting &gt;2 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug for more than 1 week unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697953",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine or stool.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be taken 1 or 2 times a day as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with juice, milk, water, or sweet foods to make it taste better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12000 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28468=[""].join("\n");
var outline_f27_51_28468=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220473\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013133\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013132\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013137\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013138\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013140\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013135\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013136\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013141\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013142\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40276?source=related_link\">",
"      Senna: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/1/42003?source=related_link\">",
"      Senna: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_51_28469="Ipratropium and albuterol: Drug information";
var content_f27_51_28469=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ipratropium and albuterol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/33/35349?source=see_link\">",
"    see \"Ipratropium and albuterol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Combivent&reg;;",
"     </li>",
"     <li>",
"      Combivent&reg; Respimat&reg;;",
"     </li>",
"     <li>",
"      DuoNeb&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Ipra-Sal;",
"     </li>",
"     <li>",
"      Combivent UDV;",
"     </li>",
"     <li>",
"      Gen-Combo Sterinebs;",
"     </li>",
"     <li>",
"      ratio-Ipra Sal UDV;",
"     </li>",
"     <li>",
"      Teva-Combo Sterinebs",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent;",
"     </li>",
"     <li>",
"      Beta",
"      <sub>",
"       2",
"      </sub>",
"      Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      COPD:",
"     </b>",
"     Inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Aerosol for inhalation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combivent&reg;: Two inhalations 4 times daily (maximum: 12 inhalations/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combivent&reg; Respimat&reg;: One inhalation 4 times daily (maximum: 6 inhalations/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Solution for nebulization:",
"     </i>",
"     Initial: 3 mL every 6 hours (maximum: 3 mL every 4 hours)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combivent&reg;: Ipratropium bromide 18 mcg and albuterol (base) 90 mcg per inhalation  (14.7 g) [contains chlorofluorocarbon, soya lecithin; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for nebulization: Ipratropium bromide 0.5 mg and albuterol (base) 2.5 mg per 3 mL (30s, 60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DuoNeb&reg;: Ipratropium bromide 0.5 mg and albuterol (base) 2.5 mg per 3 mL (30s, 60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for oral inhalation [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combivent&reg; Respimat&reg;: Ipratropium bromide 20 mcg and albuterol (base) 100 mcg per inhalation (4 g) [contains benzalkonium chloride; 120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebulization: Administer via jet nebulizer to an air compressor with an adequate air flow, equipped with a mouthpiece or face mask.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metered-dose inhaler (MDI):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combivent&reg;: Shake canister vigorously for &ge;10 seconds. Prior to first use (or if not used for &gt;24 hours), a test spray of 3 sprays is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combivent&reg; Respimat&reg;: Prior to first use (or if not used in &gt;21 days), point towards ground and actuate until aerosol cloud is seen, then repeat 3 additional times before use. If not used for &gt;3 days; actuate once before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of COPD in those patients who are currently on a regular bronchodilator who continue to have bronchospasms and require a second bronchodilator",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Combivent&reg; may be confused with Combivir&reg;, Serevent&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DuoNeb&reg; may be confused with DuoTrav&trade;, Duovent&reg; UDV",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percentages reported with combination product (not versus placebo). Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Respiratory: Bronchitis (2% to 12%), upper respiratory tract infection (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&le;3%), angina (&lt;2%), arrhythmia (&lt;2%), edema (&lt;2%), hypertension (&lt;2%), palpitation (&lt;2%), tachycardia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 6%), pain (1% to 3%), dizziness (&lt;2%), fatigue (&lt;2%), insomnia (&lt;2%), nervousness (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&lt;2%), rash (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (&le;2%), dyspepsia (&le;2%), nausea (1% to 2%), constipation (&lt;2%), dry throat (&lt;2%), sputum increased (&lt;2%), taste perversion (&lt;2%), vomiting (&lt;2%), xerostomia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&le;2%), dysuria (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), muscle spasms (&lt;2%), myalgia (&lt;2%), paresthesia (&lt;2%), tremor (&lt;2%), weakness (&lt;2%), leg cramps (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye pain (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Lung disease (6%), dyspnea (2% to 5%), cough (3% to 7%), pharyngitis (2% to 4%), bronchospasm (&lt;2%), pharyngolaryngeal pain (&lt;2%), wheezing (&lt;2%), respiratory disorder (3%), sinusitis (2%), pneumonia (1%), rhinitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Dysphonia (&lt;2%), flu-like syndrome (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions (angioedema of tongue, lips or face; laryngospasm, pruritus, rash, urticaria); alopecia, anaphylactic reaction, angioedema, blurred vision, CNS stimulation, conjunctival hyperemia, COPD exacerbation, corneal edema, gastrointestinal motility disorder, glaucoma, halo vision, hyperhidrosis, hypersensitivity reactions, hypotension, intraocular pressure increased, mental disorder, metabolic acidosis, mucosal ulcers, myocardial ischemia, mydriasis, narrow-angle glaucoma precipitation, stomatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to ipratropium, albuterol, atropine (and its derivatives) or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Combivent&reg; aerosol inhaler: Additional contraindication: Hypersensitivity to  soya lecithin or related food products (eg, soybean and peanut)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sympathomimetic amines sensitivity: Use albuterol with caution in patients with sensitivity to sympathomimetic amines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: Ipratropium is not indicated for the initial treatment of acute episodes of bronchospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use albuterol with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias and myocardial ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use albuterol with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use ipratropium with caution in patients with narrow-angle glaucoma; ipratropium may increase intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use albuterol with caution in hyperthyroidism; may stimulate thyroid activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use albuterol with caution in patients with hypokalemia; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/bladder neck obstruction: Use ipratropium with caution in patients with prostatic hyperplasia or bladder neck obstruction; ipratropium may cause urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use albuterol with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Ipratropium has not been specifically studied in the elderly, but it is poorly absorbed from the airways and appears to be safe in this population. Because of its minimal effect on beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors and its relatively long duration of action, albuterol is a rational choice in the elderly when a beta-agonist is indicated; oral albuterol use should be avoided in the elderly due to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Some adverse reactions may occur more frequently in children 2-5 years of age than in adults and older children. Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Soya lecithin: Combivent&reg; aerosol inhaler: Contains soya lecithin; use is contraindicated  in patients with allergy to soya lecithin or related food products (eg, soybean and peanut)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: A spacer device is recommended when using a metered-dose inhaler.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: Excessive use may result in tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: Ipratropium (Oral Inhalation) may enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5519660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5519661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F184251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The Combivent&reg; aerosol dosage form contains soya lecithin. Do not use in patients allergic to soya lecithin or related food products such as soybean and peanut.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F184250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Combivent Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18-103 mcg/ACT (14.7 g): $259.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Combivent Respimat Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-100 mcg/ACT (4 g): $288.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DuoNeb Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-2.5 (3) mg/3 mL (3 mL): $2.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ipratropium-Albuterol Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-2.5 (3) mg/3 mL (3 mL): $2.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5519664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Spirometry (FEV, FVC); weight",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atrodual (FI);",
"     </li>",
"     <li>",
"      Atrolin (TW);",
"     </li>",
"     <li>",
"      Berovent (GR);",
"     </li>",
"     <li>",
"      Besmate (TW);",
"     </li>",
"     <li>",
"      Breva (IT);",
"     </li>",
"     <li>",
"      Combipul (PH);",
"     </li>",
"     <li>",
"      Combivent (AE, AR, AT, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CI, CL, CN, CO, CR, CY, DK, DO, EC, EE, EG, ES, ET, FR, GH, GM, GN, GT, GY, HK, HN, ID, IE, IL, IQ, IR, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, OM, PA, PE, PH, PY, QA, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Combivent Aerosol (AU, NZ);",
"     </li>",
"     <li>",
"      Combivent UDV (GB, IE);",
"     </li>",
"     <li>",
"      Di-Promal (AT);",
"     </li>",
"     <li>",
"      Dospir (CH);",
"     </li>",
"     <li>",
"      Duavent (PH);",
"     </li>",
"     <li>",
"      Duolin (IN, NZ);",
"     </li>",
"     <li>",
"      Farbivent (ID);",
"     </li>",
"     <li>",
"      Ipramol (MY);",
"     </li>",
"     <li>",
"      Multivent (PH);",
"     </li>",
"     <li>",
"      Pulmodual (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Rabe KF, Hurd S, Anzueto A, et al, &ldquo;Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2007, 176(6):532&ndash;55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28469/abstract-text/17507545/pubmed\" id=\"17507545\" target=\"_blank\">",
"        17507545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8772 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28469=[""].join("\n");
var outline_f27_51_28469=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184255\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184256\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184272\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184259\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184260\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962294\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962295\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184243\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184230\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184246\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184245\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184277\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184270\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184249\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184234\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299542\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184238\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184240\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5519660\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5519661\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184251\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184250\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5519664\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184252\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184233\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184248\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/33/35349?source=related_link\">",
"      Ipratropium and albuterol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_51_28470="Alternate patient positions";
var content_f27_51_28470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Alternate patient positions for thoracic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four patient positions for sonographic detection of pleural effusion and subsequent thoracentesis are shown here. While the sitting position is generally preferred, alternative positions are utilized in patients who cannot maintain a sitting position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28470=[""].join("\n");
var outline_f27_51_28470=null;
var title_f27_51_28471="Leptomeningeal melanoma";
var content_f27_51_28471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leptomeningeal metastasis from malignant melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 607px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A)Pigmented tumor cells are seen filling the subarachnoid space over the convexity of the brain. B) The tumor cells fill the subarachnoid space (1), have grown down the Virchow-Robin spaces into the brain (2) and have breached that space to invade the brain (3).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28471=[""].join("\n");
var outline_f27_51_28471=null;
var title_f27_51_28472="Conjugated equine estrogens (systemic): Drug information";
var content_f27_51_28472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Conjugated equine estrogens (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=see_link\">",
"    see \"Conjugated equine estrogens (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/29/22998?source=see_link\">",
"    see \"Conjugated equine estrogens (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8090824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8090832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8090841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      C.E.S.&reg;;",
"     </li>",
"     <li>",
"      Congest;",
"     </li>",
"     <li>",
"      PMS-Conjugated Estrogens C.S.D.;",
"     </li>",
"     <li>",
"      Premarin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8090845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8090925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer palliation, metastatic disease in selected patients (males and females):",
"     </b>",
"     Oral: 10 mg 3 times/day for at least 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uremic bleeding (unlabeled use):",
"     </b>",
"     I.V.: 0.6 mg/kg/day for 5 days (Livio, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Androgen-dependent prostate cancer palliation (males):",
"     </b>",
"     Oral: 1.25-2.5 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of postmenopausal osteoporosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling: Initial: 0.3 mg/day cyclically* or daily, depending on medical assessment of patient. Dose may be adjusted based on bone mineral density and clinical response. The lowest effective dose should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: 0.625 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Menopause (moderate-to-severe vasomotor symptoms):",
"     </b>",
"     Oral: Initial: 0.3 mg/day. May be given cyclically* or daily, depending on medical assessment of patient. Adjust dose based on patient&rsquo;s response. The lowest dose that will control symptoms should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vulvar and vaginal atrophy:",
"     </b>",
"     Oral: Initial: 0.3 mg/day. The lowest dose that will control symptoms should be used. May be given cyclically* or daily, depending on medical assessment of patient. Adjust dose based on patient&rsquo;s response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female hypogonadism:",
"     </b>",
"     Oral: 0.3-0.625 mg/day given cyclically*; dose may be titrated in 6- to 12-month intervals; progestin treatment should be added to maintain bone mineral density once skeletal maturity is achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female castration, primary ovarian failure:",
"     </b>",
"     Oral: 1.25 mg/day given cyclically*; adjust according to severity of symptoms and patient response. For maintenance, adjust to the lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Abnormal uterine bleeding:",
"     </b>",
"     Acute/heavy bleeding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral (unlabeled route): 10-20 mg/day in 4 divided doses has been used in place of I.M./I.V. doses (ACOG, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 25 mg, may repeat in 6-12 hours if needed (manufacturer's labeling)",
"     <b>",
"      or",
"     </b>",
"     25 mg I.V. repeated every 4 hours for 24 hours (ACOG, 2000). Patients who do not respond to 1-2 doses should be re-evaluated (ACOG, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should be followed by a low-dose oral contraceptive; medroxyprogesterone acetate along with or following estrogen therapy can also be given",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      *Cyclic administration:",
"     </b>",
"     Either 3 weeks on, 1 week off",
"     <b>",
"      or",
"     </b>",
"     25 days on, 5 days off",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8090924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/29/22998?source=see_link\">",
"      see \"Conjugated equine estrogens (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8090926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. A higher incidence of stroke and breast cancer was observed in women &gt;75 years in a WHI substudy.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13451155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).  Use with caution; may increase risk of fluid retention.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8090927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Use is contraindicated with hepatic dysfunction or disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8090954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premarin&reg;: 25 mg [contains lactose 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premarin&reg;: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8090843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8090936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: May also be administered intramuscularly; when administered I.V., drug should be administered slowly to avoid the occurrence of a flushing reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral tablet: Administer at bedtime to minimize adverse effects. May be administered without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abnormal uterine bleeding: High-dose therapy (eg. 10-20 mg/day) may cause nausea; consider concomitant use of an antiemetic",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8090899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS and NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with LR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, heparin with hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8090850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of vulvar and vaginal atrophy due to menopause; hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure); prostatic cancer (palliation); breast cancer (palliation); postmenopausal osteoporosis (prophylaxis); abnormal uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8090851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uremic bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8090826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Premarin&reg; may be confused with Primaxin&reg;, Provera&reg;, Remeron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral]; Strength of recommendation - strong [oral]).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8090869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages reported in postmenopausal women following oral use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (26% to 32%; placebo 28%), pain (17% to 20%; placebo 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (7% to 12%; placebo 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (15% to 17%), diarrhea (6% to 7%; placebo 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage (2% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (13% to 14%), arthralgia (7% to 14%; placebo 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (10% to 12%; placebo 11%), sinusitis: (6% to 11%; placebo 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression (5% to 8%), dizziness (4% to 6%), nervousness (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (6% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (5% to 7%), leukorrhea (4% to 7%), vaginal moniliasis (5% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (7% to 8%), leg cramps (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough increased (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional adverse reactions reported with injection; frequency not defined: Local: injection site: Edema, pain, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Alopecia, anaphylaxis, angioedema, asthma exacerbation, benign meningioma (possible growth), bloating, breast cancer, breast discharge/enlargement/tenderness, cervical secretion changes, chloasma, cholestatic jaundice, contact lens intolerance, dementia, deep vein thrombosis (DVT), dysmenorrhea, edema, endometrial cancer, endometrial hyperplasia, epilepsy exacerbation, erythema multiforme, erythema nodosum, fibrocystic breast changes, galactorrhea, gallbladder disease, glucose intolerance, gynecomastia (males), hepatic hemangiomas (enlargement), hirsutism, hypersensitivity reactions, hypertension, irritability, ischemic colitis, libido changes, melasma, MI, migraine, mood disturbances, nausea, ovarian cancer, pancreatitis, pulmonary emboli (PE), pelvic pain, porphyria exacerbation, rash, retinal vascular thrombosis, stroke, superficial venous thrombosis, thrombophlebitis, triglyceride increase, urticaria, uterine bleeding (abnormal), uterine leiomyomata (increase in size), vaginal candidiasis, vomiting, weight changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8090856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema or anaphylactic reaction to estrogens or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); active or history of arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (except in appropriately selected patients being treated for metastatic disease); estrogen-dependent tumor; hepatic dysfunction or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Endometrial hyperplasia; partial or complete vision loss due to ophthalmic vascular disease; migraine with aura",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8090857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/angioedema: Anaphylaxis requiring emergency medical management has been reported within minutes to hours of taking conjugated estrogen (CE) tablets. Angioedema involving the face, feet, hands, larynx, and tongue has also been reported. Exogenous estrogens may exacerbate symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012).  An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; discontinue if pancreatitis occurs. Use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Adverse cardiovascular events have also been reported in males taking estrogens for prostate cancer. Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroidism: Use caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease. Canadian labeling contraindicates use in migraine with aura.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of oral estrogen (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other nonestrogen medications are not considered appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis. When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered (NAMS, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8090878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8090879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8090883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen plasma concentrations and risk of breast cancer). Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Folic acid absorption may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8090852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are not indicated for use during pregnancy or immediately postpartum. In general, the use of estrogen and progestin as in combination hormonal contraceptives have not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8090854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8090855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogen has been shown to decrease the quantity and quality of human milk. Use only if clearly needed. Monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8090928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis. Powder for reconstitution for injection (25 mg) contains lactose 200 mg.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8090956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Premarin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $172.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Premarin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (100): $311.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45 mg (100): $311.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625 mg (100): $311.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9 mg (100): $311.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $311.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8090941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of osteoporosis: Bone density measurement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uremic bleeding: Bleeding time",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8090902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: &lt;10 mcg/24 hours (SI: &lt;35 &mu;mol/day) (values at Mayo Medical Laboratories)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 15-40 mcg/24 hours (SI: 52-139 micromole/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Menstruating: 15-80 mcg/24 hours (SI: 52-277 micromole/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postmenopausal: &lt;20 mcg/24 hours (SI: &lt;69 micromole/day)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Belestar (AR);",
"     </li>",
"     <li>",
"      Climarest (DE);",
"     </li>",
"     <li>",
"      Climatrol (CO);",
"     </li>",
"     <li>",
"      Climatrol E (CN, PY, VE);",
"     </li>",
"     <li>",
"      Dagynil (NL);",
"     </li>",
"     <li>",
"      Equin (HK);",
"     </li>",
"     <li>",
"      Estermax (CO);",
"     </li>",
"     <li>",
"      Estranova (PE);",
"     </li>",
"     <li>",
"      Estrarona (PY, UY);",
"     </li>",
"     <li>",
"      Estrinolon (BR);",
"     </li>",
"     <li>",
"      Estromon FC (TH);",
"     </li>",
"     <li>",
"      Eyzu (TW);",
"     </li>",
"     <li>",
"      Femavit (DE);",
"     </li>",
"     <li>",
"      Ladies Pearl (TW);",
"     </li>",
"     <li>",
"      Menostat (VE);",
"     </li>",
"     <li>",
"      Minoprin (BR);",
"     </li>",
"     <li>",
"      Oestro-Feminal (DE);",
"     </li>",
"     <li>",
"      Premarin (BG, BR, CL, CR, GB, GT, HK, HN, IE, IL, IN, IT, MY, NI, PA, PE, PH, PK, RU, SG, SV, TH, TR, TW, VE);",
"     </li>",
"     <li>",
"      Premarin CD (AR);",
"     </li>",
"     <li>",
"      Premina (KP);",
"     </li>",
"     <li>",
"      Presomen (DE);",
"     </li>",
"     <li>",
"      Primax (PH);",
"     </li>",
"     <li>",
"      Profemina (CN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8090900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conjugated estrogens contain a mixture of estrone sulfate, equilin sulfate, 17 alpha-dihydroequilin, 17 alpha-estradiol and 17 beta-dihydroequilin. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8090903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Binds to sex-hormone-binding globulin and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; estradiol is converted to estrone and estriol; also undergoes enterohepatic recirculation (avoided with vaginal administration); estrone sulfate is the main metabolite in postmenopausal women",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Total estrone: 27 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Total estrone: 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily estriol, also as estradiol, estrone, and conjugates",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin, \"Management of Anovulatory Bleeding,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2000, 95(3):1-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeVore GR, Owens O, and Kase N, \"Use of Intravenous Premarin in the Treatment of Dysfunctional Uterine Bleeding -- A Double-Blind Randomized Control Study,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1982, 59(3):285-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/6281704/pubmed\" id=\"6281704\" target=\"_blank\">",
"        6281704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(7):605-13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Livio M, Mannucci PM, Vigano G, et al, &ldquo;Conjugated Estrogens for the Management of Bleeding Associated With Renal Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1986, 315(12):731-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/3018561/pubmed\" id=\"3018561\" target=\"_blank\">",
"        3018561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCarthy ML and Stoukides CA, &ldquo;Estrogen Therapy of Uremic Bleeding,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(1):60-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/8123965/pubmed\" id=\"8123965\" target=\"_blank\">",
"        8123965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society (NAMS), ''The Role of Local Vaginal Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women: 2007 Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2007,14(3 Pt 1):355-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/17438512/pubmed\" id=\"17438512\" target=\"_blank\">",
"        17438512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The Writing Group for the PEPI Trial, &ldquo;Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 273(3):199-208.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/51/28472/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wassertheil-Smoller S, Hendrix S, Limacher M, et al, &ldquo;Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women's Health Initiative: A Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289:2673-84.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9123 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28472=[""].join("\n");
var outline_f27_51_28472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090824\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090832\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090841\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090845\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090925\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090924\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090926\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13451155\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090927\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090954\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090843\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090936\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090899\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090850\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090851\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090826\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090869\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090856\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090857\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090878\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090879\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090883\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090852\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090854\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090855\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090928\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090956\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090941\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090902\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961972\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090900\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090903\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9123\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9123|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/17/41238?source=related_link\">",
"      Conjugated equine estrogens (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/29/22998?source=related_link\">",
"      Conjugated equine estrogens (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=related_link\">",
"      Conjugated equine estrogens (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/48/17158?source=related_link\">",
"      Conjugated equine estrogens (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/30/14821?source=related_link\">",
"      Conjugated equine estrogens (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_51_28473="Sleepwalking and other parasomnias in children";
var content_f27_51_28473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sleepwalking and other parasomnias in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/51/28473/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28473/contributors\">",
"     Suresh Kotagal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/51/28473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28473/contributors\">",
"     Ronald D Chervin, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/51/28473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28473/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/51/28473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27172738\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasomnias are episodic behaviors that intrude onto sleep. Sleep quality generally remains unaffected, but the events lead to significant worry for the parents or the patient. The events are most common in preschool-aged children, and they gradually decrease in frequency over the first decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/1\">",
"     1",
"    </a>",
"    ]. The events may mimic sleep-related epileptic seizures; thus, it is important to understand their clinical and sleep laboratory diagnostic features. Sometimes parasomnias are isolated symptoms in an otherwise healthy child, while on other occasions they coexist with neurologic, psychiatric, or medical disorders. This article provides an overview of common parasomnias of childhood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172745\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of parasomnias in childhood have provided cross-sectional data. There are few long-term studies.",
"   </p>",
"   <p>",
"    Young children (aged 2.5 to 6 years) were evaluated in a large study in Quebec, Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/2\">",
"     2",
"    </a>",
"    ]. Parasomnias were ubiquitous: 88 percent of the cohort manifested at least one parasomnia during the study period. Parasomnias were noted at the following frequencies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep terrors &ndash; 40 percent",
"     </li>",
"     <li>",
"      Sleepwalking &ndash; 15 percent",
"     </li>",
"     <li>",
"      Sleep enuresis &ndash; 25 percent",
"     </li>",
"     <li>",
"      Bruxism (teeth grinding) &ndash; 46 percent",
"     </li>",
"     <li>",
"      Rhythmic movements (eg, head banging) &ndash; 9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older children (aged 6 to 11 years) were evaluated as part of the Tucson Children's Assessment of Sleep Apnea Study (TuCASA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/1\">",
"     1",
"    </a>",
"    ]. Each parasomnia was noted by parents with the following frequency at baseline, and remission rate approximately five years later:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep terrors &ndash; 0.6 percent at baseline, 100 percent resolved",
"     </li>",
"     <li>",
"      Sleepwalking &ndash; 6 percent at baseline, 65 percent resolved",
"     </li>",
"     <li>",
"      Sleep talking &ndash; 1 percent at baseline, 50 percent resolved",
"     </li>",
"     <li>",
"      Sleep enuresis &ndash; 0.3 percent at baseline, 71 percent resolved",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One limitation in estimates of incidence and prevalence of parasomnias during childhood is that they are based mainly on parental recall. Another is that mild and infrequent parasomnias, such as a confusional arousal with no vocalization may not even come to parental attention. There does not seem to be a gender predisposition for any specific parasomnia. Some parasomnias show a familial predisposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172752\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most parasomnias are associated with a specific type of sleep (rapid eye movement [REM] or non-rapid eye movement [NREM] sleep). This characteristic is used in the classification scheme outlined in the International Classification of Sleep Disorders, second edition (ICSD-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common parasomnias and other behaviors during sleep are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef69704 \" href=\"UTD.htm?37/1/37915\">",
"     table 1",
"    </a>",
"    ) and detailed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172788\">",
"    <span class=\"h1\">",
"     DISORDERS OF AROUSAL FROM NON-RAPID EYE MOVEMENT (NREM) SLEEP",
"    </span>",
"   </p>",
"   <p>",
"    Confusional arousals, sleep terrors, and sleepwalking are the most significant parasomnias associated with NREM sleep. They are also termed disorders of partial arousal as they result from incomplete arousal from NREM sleep. Typically, they occur at the transition from deep NREM (stage N3) sleep into the lighter stages of NREM sleep (N1 or N2) or into the awake state. They are most likely to arise during the first third of nocturnal sleep because N3 sleep is most prevalent at this time of the night [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/4\">",
"     4",
"    </a>",
"    ]. These arousal parasomnias have distinct clinical manifestations, but the underlying pathophysiology and course is similar (",
"    <a class=\"graphic graphic_table graphicRef81349 \" href=\"UTD.htm?1/20/1356\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17024214\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three arousal parasomnias have similar predisposing characteristics and triggers, suggesting common pathophysiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic predisposition &mdash; Several studies have shown familial patterns for arousal parasomnias. In a study of 323 pairs of twins (199 monozygotic, 124 dizygotic), the pair-wise concordance for sleepwalking was six times higher in the monozygotic twins than in the dizygotic twins [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Another study found that sleep terrors were twice as common in children whose parents had exhibited sleepwalking (11 percent) as compared with children whose parents did not (5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/7\">",
"       7",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Increased arousal from sleep &mdash; Disorders that increase arousals from sleep such as obstructive sleep apnea, restless legs syndrome, periodic limb movement of sleep, or gastroesophageal reflux are common triggers for arousal parasomnias. In a study of 84 children with recurrent or chronic sleepwalking, 58 percent had a history suggestive of obstructive sleep apnea, the treatment of which frequently led to resolution of sleepwalking [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/8\">",
"       8",
"      </a>",
"      ]. Separation anxiety also may be a predisposing factor for both sleep terrors and sleepwalking [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other triggers &mdash; Sleep deprivation and fever are common triggers for all three arousal parasomnias.",
"     </li>",
"     <li>",
"      Age &mdash; Vulnerability to arousal parasomnias is also influenced by age; these disorders are most common in childhood and gradually resolve in adolescence.",
"     </li>",
"     <li>",
"      Electroencephalogram (EEG) &mdash; Arousal parasomnias are associated with increased frequency of cyclic alternating patterns on sleep EEG. These are repeated and spontaneous high voltage patterns that recur at regular intervals of up to two minutes in duration [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/9\">",
"       9",
"      </a>",
"      ]. They are a reliable marker of unstable sleep and are increased during the slow wave sleep of children with sleep terrors [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17024133\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confusional arousals, sleep terrors, and sleepwalking are typically seen in toddlers and school-aged children. Sometimes, more than one of these parasomnias may be seen in the same child. Most patients show gradual, spontaneous resolution of the events over months to years, although sleepwalking is somewhat more likely to persist into adolescence. (See",
"    <a class=\"local\" href=\"#H27172745\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172803\">",
"    <span class=\"h3\">",
"     Confusional arousals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confusional arousals are most commonly reported in toddlers and usually diminish in frequency after five years of age. In a population-based study, the prevalence in children 3 to 13 years of age was 17.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/3\">",
"     3",
"    </a>",
"    ]. The onset of symptoms is typically within two to three hours of sleep onset but also may occur upon attempted awakening from sleep during the night or in the morning. The child will typically sit up in bed, whimper, cry, or moan, and may utter words like &ldquo;no&rdquo; or &ldquo;go away,&rdquo; appear distressed, and remain inconsolable regardless of all effort at soothing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/4\">",
"     4",
"    </a>",
"    ]. There is generally no sweating, flushing of the face, or stereotypic motor behavior. The child may remain sitting in the bed. The duration is 5 to 30 minutes. A simultaneously recorded EEG may show generalized, high amplitude rhythmic delta or theta activity.",
"    <em>",
"    </em>",
"    The following morning, the patient awakens, feeling alert and refreshed, and has no recollection of the event whatsoever. The events, though benign, lead to significant parental concern, worry, and puzzlement about the nature of the events and how to deal with them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172810\">",
"    <span class=\"h3\">",
"     Sleep terrors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep terrors typically occur between 4 and 12 years of age.",
"    <em>",
"    </em>",
"    The events occur during the first third of nocturnal sleep. The child awakens abruptly from sleep with a loud scream, is agitated, and has a flushed face, sweating, and tachycardia. The child may jump out of bed as if running away from an unseen threat [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/10\">",
"     10",
"    </a>",
"    ] and is usually unresponsive to parental efforts at calming. The child usually does not remember the episode later.",
"   </p>",
"   <p>",
"    A simultaneously obtained EEG may show high amplitude, rhythmic delta, or theta activity. There is a strong genetic predisposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172817\">",
"    <span class=\"h3\">",
"     Sleepwalking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleepwalking, like the other arousal parasomnias, occurs in about 15 percent of children, peaking between age 8 and 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/11\">",
"     11",
"    </a>",
"    ]. Mild episodes, in which a toddler sits up and crawls around the bed or walks up quietly to stand by the bed of the parents, may initially go unnoticed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/4,10,12\">",
"     4,10,12",
"    </a>",
"    ]. Other children may become agitated and run around the house or have inappropriate behaviors. Some patients have injured themselves by unconsciously carrying out dangerous behaviors like leaving the house on cold, wintry nights and have had consequences like accidental hypothermia. Autonomic dysfunction may coexist in the form of sweating and flushing of the face. Some patients exhibit a combination of sleep terrors and sleep walking, though one type predominates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172825\">",
"    <span class=\"h2\">",
"     Differential diagnosis of arousal parasomnias",
"    </span>",
"   </p>",
"   <p>",
"    Nocturnal seizures &ndash; Nocturnal seizures can mimic the arousal parasomnias; disorganized bodily movements, staring, unresponsiveness, vocalizations, and confused behavior are common to both seizures and arousal parasomnias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A number of features including age of onset and nocturnal pattern help distinguish arousal parasomnias from seizures (",
"    <a class=\"graphic graphic_table graphicRef60188 \" href=\"UTD.htm?15/13/15580\">",
"     table 3",
"    </a>",
"    ). Nocturnal frontal lobe epilepsy is due to mutations in the genes",
"    <em>",
"     CHRNA2",
"    </em>",
"    ,",
"    <em>",
"     CHRNA4,",
"    </em>",
"    or",
"    <em>",
"     CHRNB2",
"    </em>",
"    that",
"    <em>",
"    </em>",
"    regulate the expression of nicotinic acetyl choline receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. A 16 to 18 channel EEG montage should be incorporated into the polysomnogram for the investigation of any nocturnal events that are suspected to be seizures. Home video recordings of the spells made by the parents are invaluable aids in diagnosis because a stay in the artificial environment of the sleep laboratory is not consistently associated with capture of the nocturnal events. Clinical features that help distinguish nocturnal seizures from parasomnias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link&amp;anchor=H10#H10\">",
"     \"Nonepileptic paroxysmal disorders in children\", section on 'Sleep disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastroesophageal reflux &ndash; Gastroesophageal reflux can lead to episodes of abrupt arousal from sleep in association with crying or tonic extension of the trunk and extremities. A simultaneously obtained EEG fails to reveal epileptiform abnormalities. There may be an associated cough. Reflux episodes may also occur during wakefulness. The suspicion of reflux can be supported by esophageal pH monitoring (obtained after consultation with a pediatric gastroenterologist), but a firm association between reflux and the arousal is difficult to establish unless the events are captured simultaneously during the pH monitoring study.",
"   </p>",
"   <p>",
"    Panic attacks &ndash; Panic attacks are characterized by an abrupt awakening from NREM sleep with a sensation of choking or tightness in the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/18\">",
"     18",
"    </a>",
"    ]. The EEG remains normal. The events may last a few minutes and then subside. Daytime episodes of anxiety also may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172832\">",
"    <span class=\"h2\">",
"     Management of arousal parasomnias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most healthy children presenting with arousal parasomnias require only a focused history and physical examination for diagnosis. Parasomnias that are infrequent (one to two times per month) or that have typical triggers such as sleep deprivation or fever generally do not require further investigation, especially if there is a family history of childhood parasomnias. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172840\">",
"    <span class=\"h3\">",
"     Investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with frequent arousal parasomnias, indications for nocturnal polysomnography (PSG, sleep study) include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Habitual snoring, observed apneas,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      daytime somnolence, behavioral problem, or mood disturbance, suggesting underlying obstructive sleep apnea as a potential trigger [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leg discomfort or involuntary jerking movements during sleep suggestive of restless leg syndrome or periodic limb movements of sleep.",
"     </li>",
"     <li>",
"      Safety concerns because of dangerous behaviors during the parasomnia, excessive disruption of the family members&rsquo; sleep, or if pharmacotherapy is contemplated. &nbsp;",
"     </li>",
"     <li>",
"      Atypical features that raise concern for nocturnal seizures are daytime neurological symptoms, highly stereotyped behaviors, older age group, and multiple occurrences on a single night (",
"      <a class=\"graphic graphic_table graphicRef60188 \" href=\"UTD.htm?15/13/15580\">",
"       table 3",
"      </a>",
"      ). In this case, the PSG should include a 16 to 18 channel electroencephalogram. (See",
"      <a class=\"local\" href=\"#H27172825\">",
"       'Differential diagnosis of arousal parasomnias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the PSG shows greater than five periodic limb movements per hour of sleep or there is a history of restless legs syndrome, the serum ferritin level should be measured. Iron deficiency is present in up to 75 percent of children with restless legs syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=see_link\">",
"     \"Restless legs syndrome and periodic limb movement disorder in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstructive sleep apnea is suggested if the PSG reveals more than one apnea or hypopnea per hour of sleep (apnea-hypopnea index &ge;1), increased respiratory event-related arousals, or increased levels of end tidal carbon dioxide. The interpretation of the PSG features of sleep apnea is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Diagnostic criteria'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172848\">",
"    <span class=\"h3\">",
"     General strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently occurring (one to two times per month) confusional arousals, sleep terrors, and sleepwalking do not need to be treated. Parents should be informed about the benign and self limiting nature of the disturbance, and that the symptoms usually will resolve spontaneously over one to two years. Toddlers should be given adequate time to nap during the day because sleep deprivation may be a trigger for the parasomnia. In the case of sleepwalking, the clinician should discuss environmental safety issues with the parents, such as ensuring that the child is not able to leave the house or otherwise injure him or herself while sleepwalking. Unless the child is in a position to get injured, parents should be advised to not restrain or awaken the child as this may exacerbate the disturbance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172856\">",
"    <span class=\"h3\">",
"     Medical/surgical strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no specific underlying triggers are found and the parasomnias remain problematic, we suggest a low dose of a benzodiazepine (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    in a dose of 0.125 to 0.5 mg at bed time).",
"   </p>",
"   <p>",
"    If the serum ferritin level is below 50",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    in a child with restless legs syndrome or periodic limb movements of sleep, we suggest oral iron therapy 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with orange juice or vitamin C for four to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/23\">",
"     23",
"    </a>",
"    ]. The objective is to raise the serum ferritin level to 70 to 75",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    This is because the parasomnia may be triggered by restless legs syndrome, as described above. (See",
"    <a class=\"local\" href=\"#H27172840\">",
"     'Investigations'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    If the PSG indicates mild obstructive sleep apnea (eg, an apnea hypopnea index between one and three events per hour), and if there are no symptoms suggestive of more severe sleep apnea, it is reasonable to do a trial of treatment with nasal corticosteroids (one puff twice a day) combined with saline nasal spray (one spray two to three times a day). If this treatment fails to resolve the parasomnia, or if the PSG shows moderate to severe OSA (apnea-hypopnea index &ge;3 events per hour), a referral should be made to a pediatric otolaryngologist to evaluate the child for possible adenotonsillectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link\">",
"     \"Management of obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172863\">",
"    <span class=\"h3\">",
"     Behavioral measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticipatory awakening (scheduled awakening) is a behavioral technique that can be utilized to prevent arousal parasomnias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Because these events generally occur during the first third of the night, momentary awakening of the child by the parent, about 15 to 20 minutes prior to the usual time of occurrence may alter the sleep state and abort the event. During the scheduled awakening attempt, the parent comforts the child and generally behaves as he or she would when awakened by the child. In one report of three children with frequent sleep walking, nightly anticipatory awakenings for one month led to near-resolution of the symptom, and the improvement continued at follow up six months later [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/26\">",
"     26",
"    </a>",
"    ]. Anecdotal reports from the children&rsquo;s parents suggest that the scheduled awakenings may have conditioned the children to self-arouse prior to transitioning from slow-wave sleep, but this hypothesis has not been further examined.",
"   </p>",
"   <p>",
"    Although the efficacy of scheduled awakenings has not been well tested in clinical studies, the technique may be worth trying when the family is reluctant to administer medications and is inclined towards non-pharmacologic management. It has the potential drawback of actually triggering a parasomnia by the awakening procedure. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172877\">",
"    <span class=\"h1\">",
"     PARASOMNIAS USUALLY ASSOCIATED WITH RAPID EYE MOVEMENT (REM) SLEEP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172885\">",
"    <span class=\"h2\">",
"     Nightmares",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nightmares are disturbing dreams that awaken the dreamer. The International Classification of Sleep Disorders II defines nightmares as &ldquo;recurrent episodes of awakening from sleep with recall of intensely disturbing dream mentation, usually involving fear or anxiety, but also anger, sadness, disgust, and other dysphoric emotions&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/27\">",
"     27",
"    </a>",
"    ]. Full alertness generally returns immediately upon awakening after a nightmare and recall of the dream experience remains intact. Since REM sleep predominates during the final third of the night, nightmares generally occur in the early hours of the morning.",
"   </p>",
"   <p>",
"    The recall of dream content is good in children who are verbal. The description of dreams in preschool age children may be simple, but more elaborate in older children. Nightmares are more common in children with post-traumatic stress disorder, and their dream content may be particularly distressing, with themes of inflicted violence, death, or separation from close family members.",
"   </p>",
"   <p>",
"    Because muscle tone and mobility are actively inhibited during REM sleep, bodily movement is rare. Autonomic manifestations like sweating and flushing of the face also do not occur. Mild tachycardia may occur. The duration of the event is generally brief. After waking up, the child may find it hard to fall back to sleep.",
"   </p>",
"   <p>",
"    The association between anxiety symptoms and nightmares was explored in a group of 610 children who were evaluated at the ages of 13 and 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/28\">",
"     28",
"    </a>",
"    ]. Anxiety symptoms were classified based on DSM-III criteria for separation anxiety, overanxious disorder, and generalized anxiety disorder. As compared to boys, girls were more likely to report disturbing dreams, and the symptom tended to increase over time. The frequent occurrence of disturbing dreams at age 13 years was associated with generalized anxiety disorder, separation anxiety, or overanxious disorder at age 16 years for both boys and girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172892\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysomnography is not routinely indicated for the investigation of nightmares. When nightmares are recurrent and problematic, psychological evaluation is indicated to assess for anxiety and determine its underlying causes. &nbsp;",
"   </p>",
"   <p>",
"    Medications are rarely indicated for treatment of nightmares. Triggers for nightmares include certain medications, including antidepressants, antihypertensives, and antihistamines. Behavioral techniques to manage nightmares in children are based on observations from small, non-randomized case series, and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reassurance &ndash; Some nightmares may subside simply with reassurance.",
"     </li>",
"     <li>",
"      Rescripting &ndash; Rescripting techniques in which children are taught to create new, more pleasant endings to recurring nightmares may lessen their distress.",
"     </li>",
"     <li>",
"      Desensitization &ndash; Desensitization techniques may also help alleviate the fear of nightmares [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/29\">",
"       29",
"      </a>",
"      ]. Some therapists have found it useful to encourage the child to write down the content of the nightmare, or draw pictures of the object(s) which may help make the experience less scary.",
"     </li>",
"     <li>",
"      Hypnotherapy &ndash; A small case series suggested that one or two sessions of hypnotherapy will help adults and children with nightmares, with",
"      <span class=\"nowrap\">",
"       5/7",
"      </span>",
"      (71 percent) remaining free of nightmares or much improved at 18 months follow up, and",
"      <span class=\"nowrap\">",
"       4/6",
"      </span>",
"      (67 percent) remaining free of nightmares after five years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive behavioral therapy (CBT) &ndash; CBT may be of value in cases of intense, disturbing nightmares but is not well studied in children or adults [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/31\">",
"       31",
"      </a>",
"      ]. Techniques include imagery rehearsal therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172907\">",
"    <span class=\"h2\">",
"     Rapid eye movement sleep behavior disorder (RBD)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172900\">",
"    <span class=\"h3\">",
"     Clinical features and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid eye movement sleep behavior disorder (RBD) is characterized by aggressive motor behavior as part of dream enactment, resulting from loss of muscle atonia during REM sleep and often leading to injury. At the end of an episode, the dreamer typically awakens quickly and is able to recall the dream content, which tends to correspond to the observed sleep behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast to the arousal parasomnias discussed above, RBD tends to occur during the later part of the night, when REM sleep predominates. &nbsp;",
"   </p>",
"   <p>",
"    RBD occurs in less than 1 percent of adults (usually in men older than 50 years), in whom it is predictive of degenerative synucleinopathies such as Parkinson disease and Lewy Body dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/34\">",
"     34",
"    </a>",
"    ]. RBD also may be associated with narcolepsy or use of antidepressant medications including selective serotonin reuptake inhibitors (SSRIs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\", section on 'REM sleep disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBD also occurs rarely in children, although it is probably under-recognized. Case reports describe two girls aged seven and nine years with combined REM sleep behavior disorder and narcolepsy-cataplexy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/35\">",
"     35",
"    </a>",
"    ]. The largest series of children with RBD to date (n = 15), reveals a preponderance of neurodevelopmental disorders such as Smith Magenis syndrome and autism, structural brainstem abnormalities such as Chiari type I malformation, narcolepsy, or use of SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nocturnal polysomnogram in RBD often shows a lack of chin muscle atonia that normally characterizes physiologic REM sleep. Excessive twitching and movement of the limbs during REM sleep also may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/37\">",
"     37",
"    </a>",
"    ]. Videotapes sometimes document yelling, agitation, or flailing of the limbs, although such behaviors are often absent when sleep is recorded in a sleep laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172931\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for RBD are based on small case series in adults and anecdotal experience in children. If the patient is taking medications known to exacerbate RBD (which include SSRIs), discontinuation of the medication (when possible) may lead to improvement or resolution of the RBD. As in adults, RBD in children responds promptly to treatment with benzodiazepines like",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    , 0.125 to 0.5 mg at bed time. Melatonin appears to be useful for adults with RBD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]; in children we have used a dose of 1 to 3 mg at bedtime with some success. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=see_link&amp;anchor=H7685558#H7685558\">",
"     \"Prognosis and treatment of dementia with Lewy bodies\", section on 'REM sleep disorder'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Patients with compressive brainstem lesions such as Chiari malformation require treatment measures directed specifically to these disorders. The same applies to neurodevelopmental disabilities like Smith-Magenis syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26697?source=see_link\">",
"     \"Chiari malformations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=see_link&amp;anchor=H86262802#H86262802\">",
"     \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '17p11.2 deletion syndrome (Smith-Magenis syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172938\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of childhood RBD is not known, but the clinical course may differ from that of adults with this disorder because there does not seem to be an association with neurodegeneration involving synuclein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17023859\">",
"    <span class=\"h3\">",
"     Parasomnia overlap disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasomnia overlap disorder consists of RBD and an arousal parasomnia (sleepwalking, sleep terrors, or confusional arousals) occurring in the same patient, and has been reported in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/33\">",
"     33",
"    </a>",
"    ]. Like RBD, many of the cases are associated with underlying neurologic disease. Obstructive sleep apnea or other causes of partial arousal from both NREM and REM sleep should also be considered. However, idiopathic disease also occurs and is more common among patients presenting with parasomnia overlap disorder at a younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17024029\">",
"    <span class=\"h2\">",
"     Sleep paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle atonia and transient skeletal muscle paralysis are physiologic properties of rapid eye movement (REM) sleep. These phenomena may however sometimes intrude onto wakefulness around the time of sleep onset or at the time of waking up from sleep. The resulting transient inability to move the body is called sleep paralysis. Recurrent sleep paralysis is often associated with narcolepsy. If it is not associated with narcolepsy, it is known as isolated sleep paralysis (ISP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H12#H12\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Narcolepsy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    During a sleep paralysis episode, consciousness remains intact, and the individual is perfectly aware of the surroundings. For a patient unfamiliar with the phenomenon, a terrifying feeling can arise from the sudden inability to move the body while being fully awake, albeit momentarily. The child may also experience hallucinations such as feeling the presence of others nearby, feeling pressure on the chest, or hearing footsteps [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/4\">",
"     4",
"    </a>",
"    ]. Approximately 20 percent of young adults with anxiety disorder may manifest ISP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/41\">",
"     41",
"    </a>",
"    ]. Sleep deprivation in otherwise healthy teenagers is also a common trigger. The differential diagnosis includes partial seizures, periodic paralysis, and narcolepsy. Occasional events are generally due to sleep deprivation and do not require treatment. Recurrent episodes may be very bothersome to the patient. Treatment approaches have not been evaluated. For patients with an underlying anxiety disorder, treatment for the anxiety is appropriate and may alleviate the ISP. In our practice, we have had some success treating ISP with REM-suppressing agents such as low doses of tricyclic agents,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172945\">",
"    <span class=\"h1\">",
"     OTHER PARASOMNIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27172953\">",
"    <span class=\"h2\">",
"     Sleep enuresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep enuresis (also known as nocturnal enuresis) is defined as discrete episodes of urinary incontinence during sleep at least twice per week in children older than five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This age threshold is used because most children achieve control of the bladder by this age. Recurrent nocturnal enuresis affects approximately 15 percent of five-year-old children, and gradually declines to about 5 percent by 10 years of age (",
"    <a class=\"graphic graphic_figure graphicRef58087 \" href=\"UTD.htm?39/7/40061\">",
"     figure 1",
"    </a>",
"    ). Enuretic episodes can occur in all sleep stages, including during the sleep-wake transition. &nbsp;",
"   </p>",
"   <p>",
"    Primary enuresis refers to a child who has never achieved a period of dryness at night. This form is most common and has a strong familial pattern. Secondary enuresis describes a child who develops enuresis after a period of six or more months of nighttime dryness. Secondary enuresis is more likely to be associated with acquired factors such as urinary tract infection, obstructive sleep apnea (OSA), diabetes mellitus, diabetes insipidus, and psychological disturbances such as a stressful event. &nbsp;",
"   </p>",
"   <p>",
"    OSA is increasingly recognized as a cause of some cases of nocturnal enuresis. Among 69 children with nocturnal enuresis, more than half had symptoms suggestive of OSA (using a standardized questionnaire) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/44\">",
"     44",
"    </a>",
"    ]. In a different study using polysomnography to diagnose OSA, there was an association between OSA severity and nocturnal enuresis in girls, but not in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/45\">",
"     45",
"    </a>",
"    ]. Conversely, among children with established OSA, up to 40 percent have a history of nocturnal enuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Among children with enuresis and OSA, the enuresis usually resolves if the OSA is treated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The possibility of OSA should be considered in children presenting with nocturnal enuresis, particularly if they have one or more of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Habitual snoring or observed apneas",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Adenotonsillar hypertrophy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mouth-breathing",
"     </li>",
"     <li>",
"      Secondary enuresis &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evaluation of a child with suspected OSA, including the indications for and interpretation of a polysomnogram (sleep study), is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of nocturnal enuresis include nocturnal polyuria, maturational delay, and genetics. These causes, the clinical evaluation of a child presenting with this symptom, and treatment approaches (including medication) are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and evaluation of nocturnal enuresis in children\", section on 'Epidemiology and natural history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7178?source=see_link\">",
"     \"Management of nocturnal enuresis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17023605\">",
"    <span class=\"h1\">",
"     SLEEP-RELATED MOVEMENT DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17023639\">",
"    <span class=\"h2\">",
"     Rhythmic movement disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhythmic movements in some infants and toddlers that start at the time of sleep onset are physiologic, and generally resolve spontaneously by the age of three to four years. There is a 4:1 male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/4\">",
"     4",
"    </a>",
"    ]. The three common manifestations of rhythmic movements are: side to side head rolling, head banging, and body rocking. The child generally has no recollection of the event upon awakening the next morning. The term rhythmic movement disorder",
"    <em>",
"    </em>",
"    is used if the movements lead to significant consequences such as self-injury.",
"   </p>",
"   <p>",
"    Rhythmic movements occur during stages N1, N2, or N3 of NREM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/4\">",
"     4",
"    </a>",
"    ]. Infrequently, the movements develop in the middle of the night after the child has awakened and is then attempting to fall back to sleep. Rhythmic movements around the time of sleep onset should be distinguished from those seen in autism and pervasive developmental disorders; in these conditions the movements also occur during wakefulness.",
"   </p>",
"   <p>",
"    The pathophysiology of rhythmic movements is not fully understood. Their stereotypic nature, and occurrence during sleep and as one is falling to sleep suggests activation (owing to loss of suprasegmental inhibition) of central pattern generators (CPG), which are groups of motor neurons and interneurons located in the brainstem and spinal cord. Depending on the anatomic location of the CPG that has been activated, one may see different types of rhythmic behaviors. As examples, bruxism or teeth grinding may occur with activation of CPGs located within the motor nucleus of the trigeminal nerve in the pons, or body rocking may occur with activation of CPGs in the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No satisfactory treatment exists for rhythmic movement disorders. Anecdotal therapies include creating intentional and extraneous rhythmic movements before bedtime, rhythmic sounds in the sleeping environment, and the use of antihistamines or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . Sometimes, short-term benzodiazepine therapy has been justified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17023712\">",
"    <span class=\"h2\">",
"     Bruxism (teeth grinding)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bruxism is the involuntary, non-functional, and forceful clenching, grinding, or rubbing of teeth during NREM sleep. Limited evidence suggests that patients with bruxism may be prone to develop temporomandibular disorders and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/50\">",
"     50",
"    </a>",
"    ]. There is insufficient evidence to determine whether occlusive splints are effective in treating bruxism, but they may be helpful for reducing tooth wear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with neurodevelopmental disorders like Rett syndrome and Down syndrome may exhibit bruxism even during wakefulness. There is some association with anxiety; in one study, children with sleep related bruxism showed increased tendency for anxiety on the Children&rsquo;s Personality Questionnaire and the Conners Parent Rating Scale, as compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/52\">",
"     52",
"    </a>",
"    ]. Sleep disordered breathing may exacerbate an underlying tendency for bruxism; in a prospective study, adenotonsillectomy seemed to significantly lessen the incidence of bruxism from 25 to 7 percent (p=0.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3903837\">",
"    <span class=\"h2\">",
"     Restless legs syndrome/periodic limb movement disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restless legs syndrome (RLS) is a sensorimotor disorder in which patients complain of a sensation of needing to move their legs when at rest. These sensations show a circadian pattern (they are typically worst in the early evening) and are relieved by movement. Children, especially young children, may have difficulty describing the paresthesias, to the extent that &ldquo;growing pains&rdquo; can be a sign of RLS (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=see_link\">",
"     \"Growing pains\"",
"    </a>",
"    ). Sleep disturbance and a frequent association with involuntary, jerking movements of the legs during sleep, known as periodic limb movements of sleep (PLMS), are common. The RLS or PLMS may be a trigger for arousal parasomnias and are sometimes associated with iron deficiency, as discussed above (see",
"    <a class=\"local\" href=\"#H27172840\">",
"     'Investigations'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations and diagnosis of RLS are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=see_link\">",
"     \"Restless legs syndrome and periodic limb movement disorder in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17023904\">",
"    <span class=\"h1\">",
"     ISOLATED SYMPTOMS AND NORMAL VARIANTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17023943\">",
"    <span class=\"h2\">",
"     Hypnic starts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnic starts, also known as sleep starts, are isolated, quick jerks of the extremities that occur around sleep onset or at the time of waking up from sleep. They may be accompanied by a sensation of falling, a dream-like feeling, or a flashing sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypnic starts are benign and nonepileptic. There are no adverse consequences. Sometimes, however, they may be mistaken by parents as seizures. Hypnic starts can occur at all ages. They represent a release phenomenon that is mediated at the level of the brainstem or spinal cord due to a transient loss of cortical inhibition. In neurologically impaired children, hypnic starts may sometimes occur in a repetitive fashion but still do not correlate with any simultaneous epileptiform discharges on the electroencephalogram (EEG) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28473/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonepileptic paroxysmal disorders in children\", section on 'Sleep starts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/9/17554?source=see_link\">",
"       \"Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=see_link\">",
"       \"Patient information: Sleepwalking in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9110940\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parasomnias occur frequently in preschool-aged children and generally decline in frequency during the pre-adolescent years (",
"      <a class=\"graphic graphic_table graphicRef69704 \" href=\"UTD.htm?37/1/37915\">",
"       table 1",
"      </a>",
"      ). Most parasomnias occur at sleep onset or are associated with a specific type of sleep (rapid eye movement [REM] or non-rapid eye movement [NREM] sleep). (See",
"      <a class=\"local\" href=\"#H27172745\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27172752\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arousal parasomnias (confusional arousals, sleep terrors, and sleepwalking) have distinct clinical manifestations, but the underlying pathophysiology and course is similar (",
"      <a class=\"graphic graphic_table graphicRef81349 \" href=\"UTD.htm?1/20/1356\">",
"       table 2",
"      </a>",
"      ). Because they are associated with arousal from deep NREM sleep, they tend to occur during the first third of the night. There is a strong familial tendency. Triggers include any disorder that increases arousals from sleep, such as obstructive sleep apnea, restless legs syndrome, sleep deprivation, or fever. (See",
"      <a class=\"local\" href=\"#H17024214\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17024133\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Otherwise healthy children who present with arousal parasomnias often require only a focused history and physical examination for diagnosis. Parasomnias that are infrequent (one to two times per month) or that have typical triggers such as sleep deprivation or fever generally do not require further investigation. The clinician can reassure the parent about the benign nature of the disturbance and that it will probably resolve spontaneously over one to two years. The family should ensure that the child has adequate sleep. In the case of sleep walking, environmental safety issues should also be discussed. (See",
"      <a class=\"local\" href=\"#H27172848\">",
"       'General strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children with frequent arousal parasomnias, indications for nocturnal polysomnography (PSG) include: (See",
"      <a class=\"local\" href=\"#H27172840\">",
"       'Investigations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Habitual snoring, observed apneas, nocturnal enuresis, or other symptoms suggesting obstructive sleep apnea (OSA). Symptoms of OSA can be an indication for PSG even if the parasomnia does not occur frequently.",
"     </li>",
"     <li>",
"      Significant safety concerns, excessive disruption of the family members&rsquo; sleep, or contemplation of pharmacotherapy.",
"     </li>",
"     <li>",
"      Atypical features that raise concern for nocturnal seizures, such as daytime neurological symptoms, older age group, family history of seizures, and multiple occurrences on a single night (",
"      <a class=\"graphic graphic_table graphicRef60188 \" href=\"UTD.htm?15/13/15580\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27172825\">",
"       'Differential diagnosis of arousal parasomnias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the PSG or history suggests restless legs syndrome (RLS), the serum ferritin level should be measured because RLS is associated with iron deficiency. If iron deficiency is present, iron supplementation may relieve the RLS and associated parasomnia. (See",
"      <a class=\"local\" href=\"#H27172840\">",
"       'Investigations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If no specific underlying triggers are found and the arousal parasomnia remains problematic, we suggest treatment with a low dose of a benzodiazepine (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"       clonazepam",
"      </a>",
"      at a dose of 0.125 to 0.5 mg at bed time) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Anticipatory awakening is an alternative strategy but also can trigger the parasomnia. (See",
"      <a class=\"local\" href=\"#H27172856\">",
"       'Medical/surgical strategies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27172863\">",
"       'Behavioral measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nightmares are disturbing dreams that awaken the dreamer, usually involving fear or anxiety. They are more common among children with anxiety or post traumatic stress disorder. Nightmares can be triggered by certain medications, including antihypertensives and antihistamines. When nightmares are recurrent and problematic, the child should be evaluated and treated for anxiety and psychological stressors. Several cognitive-behavioral techniques have been used to treat nightmares, supported by limited evidence. (See",
"      <a class=\"local\" href=\"#H27172885\">",
"       'Nightmares'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep enuresis (nocturnal enuresis) is defined as discrete episodes of incontinence during sleep at least twice per week in children older than five years of age. It affects about 15 percent of five-year-old children and gradually declines to about 5 percent by 10 years of age (",
"      <a class=\"graphic graphic_figure graphicRef58087 \" href=\"UTD.htm?39/7/40061\">",
"       figure 1",
"      </a>",
"      ). Causes include nocturnal polyuria, maturational delay, and genetic predisposition. Obstructive sleep apnea is increasingly recognized as a treatable cause of some cases of nocturnal enuresis. (See",
"      <a class=\"local\" href=\"#H27172953\">",
"       'Sleep enuresis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=see_link\">",
"       \"Etiology and evaluation of nocturnal enuresis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhythmic movements in infants and toddlers at the time of sleep onset are physiologic and generally resolve spontaneously by the age of three to four years; they are most common in boys. The three common manifestations of rhythmic movements are: side to side head rolling, head banging, and body rocking. The term rhythmic movement disorder",
"      <em>",
"      </em>",
"      is used if the movements lead to significant consequences such as self-injury. (See",
"      <a class=\"local\" href=\"#H17023639\">",
"       'Rhythmic movement disorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/1\">",
"      Furet O, Goodwin JL, Quan SF. Incidence and Remission of Parasomnias among Adolescent Children in the Tucson Children's Assessment of Sleep Apnea (TuCASA) Study. Southwest J Pulm Crit Care 2011; 2:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/2\">",
"      Petit D, Touchette E, Tremblay RE, et al. Dyssomnias and parasomnias in early childhood. Pediatrics 2007; 119:e1016.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders: Diagnostic and coding manual, 2, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/4\">",
"      Sheldon SH. Parasomnias in childhood. Pediatr Clin North Am 2004; 51:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/5\">",
"      Bakwin H. Sleep-walking in twins. Lancet 1970; 2:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/6\">",
"      Hublin C, Kaprio J. Genetic aspects and genetic epidemiology of parasomnias. Sleep Med Rev 2003; 7:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/7\">",
"      Abe K, Amatomi M, Oda N. Sleepwalking and recurrent sleeptalking in children of childhood sleepwalkers. Am J Psychiatry 1984; 141:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/8\">",
"      Guilleminault C, Palombini L, Pelayo R, Chervin RD. Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics 2003; 111:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/9\">",
"      Parrino L, Halasz P, Tassinari CA, Terzano MG. CAP, epilepsy and motor events during sleep: the unifying role of arousal. Sleep Med Rev 2006; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/10\">",
"      Kotagal S. Parasomnias of childhood. Curr Opin Pediatr 2008; 20:659.",
"     </a>",
"    </li>",
"    <li>",
"     Sleepwalking. In: International Classification of Sleep Disorders: Diagnostic and coding manual, 2, American Academy of Sleep Medicine, Westchester, IL 2005. p.142.",
"    </li>",
"    <li>",
"     Rosen GM, Mahowald MW. Disorders of arousal in children. In: Principles and Practice of Pediatric Sleep Medicine, Sheldon SH, Ferber R, Kryger MH (Eds), Elsevier Saunders, Philadelphia 2005. p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/13\">",
"      Tinuper P, Provini F, Bisulli F, et al. Movement disorders in sleep: guidelines for differentiating epileptic from non-epileptic motor phenomena arising from sleep. Sleep Med Rev 2007; 11:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/14\">",
"      Nobili L. Nocturnal frontal lobe epilepsy and non-rapid eye movement sleep parasomnias: differences and similarities. Sleep Med Rev 2007; 11:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/15\">",
"      Aridon P, Marini C, Di Resta C, et al. Increased sensitivity of the neuronal nicotinic receptor alpha 2 subunit causes familial epilepsy with nocturnal wandering and ictal fear. Am J Hum Genet 2006; 79:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/16\">",
"      Steinlein OK, Mulley JC, Propping P, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995; 11:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/17\">",
"      D&iacute;az-Otero F, Quesada M, Morales-Corraliza J, et al. Autosomal dominant nocturnal frontal lobe epilepsy with a mutation in the CHRNB2 gene. Epilepsia 2008; 49:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/18\">",
"      Vendrame M, Kothare SV. Epileptic and nonepileptic paroxysmal events out of sleep in children. J Clin Neurophysiol 2011; 28:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/19\">",
"      Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/20\">",
"      Kotagal S, Nichols CD, Grigg-Damberger MM, et al. Non-respiratory indications for polysomnography and related procedures in children: an evidence-based review. Sleep 2012; 35:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/21\">",
"      Aurora RN, Lamm CI, Zak RS, et al. Practice parameters for the non-respiratory indications for polysomnography and multiple sleep latency testing for children. Sleep 2012; 35:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/22\">",
"      Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol 2004; 56:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/23\">",
"      Simakajornboon N, Gozal D, Vlasic V, et al. Periodic limb movements in sleep and iron status in children. Sleep 2003; 26:735.",
"     </a>",
"    </li>",
"    <li>",
"     Hopkins J, Isaacs C, Pitterle P. A developmental approach to sleep problems in toddlers. In: Clinical Handbook of Sleep Disorders in Children, Schafer CE (Ed), Aronson Inc, Northvale 1995. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/25\">",
"      Tobin JD Jr. Treatment of somnambulism with anticipatory awakening. J Pediatr 1993; 122:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/26\">",
"      Frank NC, Spirito A, Stark L, Owens-Stively J. The use of scheduled awakenings to eliminate childhood sleepwalking. J Pediatr Psychol 1997; 22:345.",
"     </a>",
"    </li>",
"    <li>",
"     Nightmare disorder. In: International Classification of Sleep Disorders: Diagnostic and coding manual, 2, American Academy of Sleep Medicine, Westchester, IL 2005. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/28\">",
"      Nielsen TA, Laberge L, Paquet J, et al. Development of disturbing dreams during adolescence and their relation to anxiety symptoms. Sleep 2000; 23:727.",
"     </a>",
"    </li>",
"    <li>",
"     Halliday G. Treating nightmares in children. In: Clinical Handbook of Sleep Disorders in Children, Schafer CE (Ed), Aronson Inc, Northvale 1995. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/30\">",
"      Hauri PJ, Silber MH, Boeve BF. The treatment of parasomnias with hypnosis: a 5-year follow-up study. J Clin Sleep Med 2007; 3:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/31\">",
"      Sadeh A. Cognitive-behavioral treatment for childhood sleep disorders. Clin Psychol Rev 2005; 25:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/32\">",
"      Krakow B, Sandoval D, Schrader R, et al. Treatment of chronic nightmares in adjudicated adolescent girls in a residential facility. J Adolesc Health 2001; 29:94.",
"     </a>",
"    </li>",
"    <li>",
"     Rapid eye movement sleep behavior disorder. In: International classification of sleep disorders: Diagnostic and coding manual, 2, American Academy of Sleep Medicine, Westchester, IL 2005. p.148.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/34\">",
"      Mahowald MW, Schenck CH. Insights from studying human sleep disorders. Nature 2005; 437:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/35\">",
"      Nevsimalova S, Prihodova I, Kemlink D, et al. REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Sleep Med 2007; 8:784.",
"     </a>",
"    </li>",
"    <li>",
"     Lloyd R, Tippman-Piekert M, Slocumb N, Kotagal S. Characteristics of rapid eye movement sleep behavior disorder in childhood. J Clin Sleep Med, 2012; in press.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/37\">",
"      Schenck CH, Mahowald MW. Motor dyscontrol in narcolepsy: rapid-eye-movement (REM) sleep without atonia and REM sleep behavior disorder. Ann Neurol 1992; 32:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/38\">",
"      Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/39\">",
"      Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology 2006; 67:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/40\">",
"      Schenck CH, Boyd JL, Mahowald MW. A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. Sleep 1997; 20:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/41\">",
"      Otto MW, Simon NM, Powers M, et al. Rates of isolated sleep paralysis in outpatients with anxiety disorders. J Anxiety Disord 2006; 20:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/42\">",
"      Nev&eacute;us T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 2006; 176:314.",
"     </a>",
"    </li>",
"    <li>",
"     Sleep enuresis. In: International classification of sleep disorders: Diagnostic and coding manual, 2, American Academy of Sleep Medicine, Westchester, IL 2005. p.162.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/44\">",
"      Bascom A, Penney T, Metcalfe M, et al. High risk of sleep disordered breathing in the enuresis population. J Urol 2011; 186:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/45\">",
"      Su MS, Li AM, So HK, et al. Nocturnal enuresis in children: prevalence, correlates, and relationship with obstructive sleep apnea. J Pediatr 2011; 159:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/46\">",
"      Brooks LJ, Topol HI. Enuresis in children with sleep apnea. J Pediatr 2003; 142:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/47\">",
"      Weissbach A, Leiberman A, Tarasiuk A, et al. Adenotonsilectomy improves enuresis in children with obstructive sleep apnea syndrome. Int J Pediatr Otorhinolaryngol 2006; 70:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/48\">",
"      Waleed FE, Samia AF, Samar MF. Impact of sleep-disordered breathing and its treatment on children with primary nocturnal enuresis. Swiss Med Wkly 2011; 141:w13216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/49\">",
"      Kotagal S. Parasomnias in childhood. Sleep Med Rev 2009; 13:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/50\">",
"      Barbosa Tde S, Miyakoda LS, Pocztaruk Rde L, et al. Temporomandibular disorders and bruxism in childhood and adolescence: review of the literature. Int J Pediatr Otorhinolaryngol 2008; 72:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/51\">",
"      Macedo CR, Silva AB, Machado MA, et al. Occlusal splints for treating sleep bruxism (tooth grinding). Cochrane Database Syst Rev 2007; :CD005514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/52\">",
"      Restrepo CC, V&aacute;squez LM, Alvarez M, Valencia I. Personality traits and temporomandibular disorders in a group of children with bruxing behaviour. J Oral Rehabil 2008; 35:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/53\">",
"      Eftekharian A, Raad N, Gholami-Ghasri N. Bruxism and adenotonsillectomy. Int J Pediatr Otorhinolaryngol 2008; 72:509.",
"     </a>",
"    </li>",
"    <li>",
"     Sateia MJ. Sleep starts. In: American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic and coding manual, 2nd, American Academy of Sleep Medicine, Westchester 2005. p.208.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28473/abstract/55\">",
"      Fusco L, Pachatz C, Cusmai R, Vigevano F. Repetitive sleep starts in neurologically impaired children: an unusual non-epileptic manifestation in otherwise epileptic subjects. Epileptic Disord 1999; 1:63.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16588 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28473=[""].join("\n");
var outline_f27_51_28473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9110940\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27172738\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27172745\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27172752\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27172788\">",
"      DISORDERS OF AROUSAL FROM NON-RAPID EYE MOVEMENT (NREM) SLEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17024214\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17024133\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172803\">",
"      - Confusional arousals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172810\">",
"      - Sleep terrors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172817\">",
"      - Sleepwalking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27172825\">",
"      Differential diagnosis of arousal parasomnias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27172832\">",
"      Management of arousal parasomnias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172840\">",
"      - Investigations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172848\">",
"      - General strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172856\">",
"      - Medical/surgical strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172863\">",
"      - Behavioral measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27172877\">",
"      PARASOMNIAS USUALLY ASSOCIATED WITH RAPID EYE MOVEMENT (REM) SLEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27172885\">",
"      Nightmares",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172892\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27172907\">",
"      Rapid eye movement sleep behavior disorder (RBD)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172900\">",
"      - Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172931\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27172938\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17023859\">",
"      - Parasomnia overlap disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17024029\">",
"      Sleep paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27172945\">",
"      OTHER PARASOMNIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27172953\">",
"      Sleep enuresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17023605\">",
"      SLEEP-RELATED MOVEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17023639\">",
"      Rhythmic movement disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17023712\">",
"      Bruxism (teeth grinding)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3903837\">",
"      Restless legs syndrome/periodic limb movement disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17023904\">",
"      ISOLATED SYMPTOMS AND NORMAL VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17023943\">",
"      Hypnic starts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9110940\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16588|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/7/40061\" title=\"figure 1\">",
"      Monosymptomatic enuresis epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/1/37915\" title=\"table 1\">",
"      Parasomnias of childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/20/1356\" title=\"table 2\">",
"      Comparison of the arousal parasomnias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/13/15580\" title=\"table 3\">",
"      Distinction between arousal parasomnias and nocturnal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26697?source=related_link\">",
"      Chiari malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40281?source=related_link\">",
"      Etiology and evaluation of nocturnal enuresis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20902?source=related_link\">",
"      Growing pains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/0/7178?source=related_link\">",
"      Management of nocturnal enuresis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=related_link\">",
"      Management of obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/9/17554?source=related_link\">",
"      Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/28/36289?source=related_link\">",
"      Patient information: Sleepwalking in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=related_link\">",
"      Prognosis and treatment of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=related_link\">",
"      Restless legs syndrome and periodic limb movement disorder in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_51_28474="Lipid lowering with diet or dietary supplements";
var content_f27_51_28474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipid lowering with diet or dietary supplements",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/51/28474/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28474/contributors\">",
"     Christine C Tangney, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28474/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/51/28474/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28474/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/51/28474/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/51/28474/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/51/28474/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid alterations can also be effected by a number of dietary approaches or specific dietary supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Such approaches have been exploited by nutritionists and physicians as evidence-based and less costly alternatives to several classes of drugs. These differ with respect to mechanism of action and to the degree and type of lipid lowering. Thus, the indications for a particular dietary supplement are influenced by the underlying lipid abnormality.",
"   </p>",
"   <p>",
"    The characteristics and efficacy of the lipid-lowering dietary supplements or dietary components will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FISH OIL AND OMEGA-3 FATTY ACIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Populations with high intakes of omega-3 (n-3) polyunsaturated fatty acids (such as the Eskimos) have low rates of heart disease; this observation has increased interest in the possible benefit of fish oils [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Rich sources of omega-3 fatty acids come from fatty fish, especially salmon, and plant sources such as flaxseed and flaxseed oil, canola oil, soybean oil, and nuts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link&amp;anchor=H14#H14\">",
"     \"Dietary fat\", section on 'Polyunsaturated fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fish oil concentrate administered at high doses (&gt;6",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    can reduce levels of triglycerides through inhibition of the synthesis of VLDL-triglycerides and apolipoprotein B [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In hypertriglyceridemic subjects, fish oils (in a dose of 15",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    lower triglyceride levels by approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Similarly large reductions in triglyceride levels with fish oil have also been seen in patients with HIV and hypertriglyceridemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\", section on 'Fish oil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since fish oil lowers plasma triglyceride concentration, which in turn is a determinant of small dense LDL, it is possible that fish oils will decrease the concentration of small LDL. Support for this hypothesis comes from the observed reduction of cholesteryl ester transfer activity following fish oil therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, several studies have observed an increase in overall LDL particle size with 4 g purified docosahexaenoic acid&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In contrast, 2.5 g of omega-3 fatty acids daily for two months did not significantly change this fraction in 16 non-insulin-dependent diabetics when compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical effects and side effects of fish oil consumption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supplementation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pharmacologic use of fish oils supplements should be restricted to patients with refractory hypertriglyceridemia. The use of fish oil for this purpose is also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Pharmacologic therapy (including fish oil)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been interest in the United States and elsewhere in particular omega-3 supplements other than fish oil, although the clinical benefits of particular supplements have generally not been adequately studied. Interventions using flaxseed appear to reduce LDL-C, but these may be limited to flaxseed and flaxseed lignans; flaxseed oil does not clearly lower LDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/14\">",
"     14",
"    </a>",
"    ]. Clinical effects of omega-3 fatty acid consumption are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link&amp;anchor=H14#H14\">",
"     \"Dietary fat\", section on 'Polyunsaturated fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SOY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soy, an excellent source of protein, also contains isoflavones, which are phytoestrogens. Isoflavones are micronutrient substances that, in nonhuman primates, have properties similar to estrogen, including an effect on cholesterol levels and inhibition on low density lipoprotein (LDL) oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/15\">",
"     15",
"    </a>",
"    ]. It has been suggested that the lower risk of heart disease among Asian compared to Western populations is due to the high consumption of soybean products.",
"   </p>",
"   <p>",
"    Although earlier trials and a meta-analysis had suggested important lipid benefits with consumption of soy protein [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/16-18\">",
"     16-18",
"    </a>",
"    ], a subsequent systematic review concluded that benefits were at most small [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/19\">",
"     19",
"    </a>",
"    ]. The systematic review found that when very large amounts of soy protein (average 50 grams daily) were substituted for other dietary proteins (about half of usual total protein intake), LDL-cholesterol concentrations decreased by an average of approximately 3 percent. No significant effect was found on HDL-cholesterol, triglycerides, or lipoprotein (a). The review also found that soy isoflavones had no effect on LDL-cholesterol or on other lipid risk factors.",
"   </p>",
"   <p>",
"    Apart from lipid effects, it is possible that intake of soy proteins has other vascular benefits. One animal study found that phytoestrogens produced endothelium-independent relaxation of coronary arteries as a result of calcium antagonism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/20\">",
"     20",
"    </a>",
"    ]. Studies in healthy humans found that the phytoestrogen genistein caused endothelium-dependent vasodilation with a similar potency to estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. This beneficial effect on endothelial function, in the absence of any change in lipids, may be related to soy isoflavones, without soy protein [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]. In a consecutive series of 126 patients with coronary artery disease, stroke or diabetes, greater isoflavone intakes (median 26",
"    <span class=\"nowrap\">",
"     mg/d,",
"    </span>",
"    range, 20 to 58) was associated with better vascular endothelial function and lower carotid atherosclerotic burden (14.5 percent relative decrease in maximum intima-media thickness). This inverse association was not observed with soy protein [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ingestion of soy protein also may be associated with adverse effects. As an example, in a study of 108 men and 105 postmenopausal women (all healthy), soy protein improved both blood pressure and lipids, but did not improve vascular function as measured by systemic arterial compliance and pulse wave velocity. Adverse effects included an increase in serum Lp(a) and a decline in endothelial function (in men only) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link&amp;anchor=H8#H8\">",
"     \"Preparations for postmenopausal hormone therapy\", section on 'Phytoestrogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not clear whether the estrogen-like activities of isoflavones increase the risk of breast cancer, as they may increase breast secretions and the proliferation of breast epithelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the recommendations and conclusions of an advisory from the Nutrition Committee of the American Heart Association that performed the review discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Substituting soy protein for other proteins does not appear to have clinically important health benefits.",
"     </li>",
"     <li>",
"      Isoflavone supplements do not appear to be of benefit and should not be taken with a goal of improving lipids and cardiovascular risk.",
"     </li>",
"     <li>",
"      When substituted for animal-derived foods, many soy foods and food products (eg, tofu, soy butter, edamame, some soy burgers, etc.) are likely to have beneficial effects on lipids and cardiovascular health because they are low in saturated fats, high in unsaturated fats, and often rich in fiber.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RED YEAST RICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red yeast rice is a fermented rice product that has been used in Chinese cuisine and medicinally to promote \"blood circulation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/27\">",
"     27",
"    </a>",
"    ]. The product contains varying amounts of a family of naturally occurring substances called monacolins that have HMG CoA reductase inhibitor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .) Other active ingredients in red yeast rice that may affect cholesterol lowering include sterols (beta-sitosterol, campesterol, stigmasterol, sapogenin), isoflavones, and monounsaturated fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of red yeast rice for cholesterol lowering was evaluated in a prospective, double-blind study in which 83 patients with hyperlipidemia (total cholesterol 204 to 338",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.28&ndash;8.74",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    LDL-C 128 to 277",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.31&ndash;7.16",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    who were not receiving cholesterol lowering therapy were randomly assigned to receive red yeast rice (2.4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or placebo; both groups were also advised to follow a cholesterol lowering diet [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/29\">",
"     29",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The total cholesterol concentration decreased significantly between baseline and eight weeks in the red yeast rice compared with the placebo-treated group (208 versus 251",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.38 vs 6.57",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      The LDL-C concentration also decreased significantly in the red yeast rice group (135 versus 175",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.49 versus 4.53",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      HDL-C was unaffected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the monacolins in the red yeast rice extract used in this study, monacolin K, is the active ingredient in the HMG CoA reductase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    . The daily lovastatin content of red yeast rice was 0.2 percent of the total product, which at a total dose of red yeast rice of 2.4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    translates into a daily lovastatin dose of 4.8 mg. This is considerably lower than the average 20 to 40 mg dose of lovastatin used in clinical trials of cholesterol lowering, suggesting that other active ingredients in red yeast rice probably also contributed to its cholesterol lowering activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have also found that red yeast rice lowers total and LDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In one randomized trial, patients who had discontinued statin therapy because of myalgias tolerated treatment with red yeast rice 1800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at a rate similar to placebo, while achieving significant reductions in LDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/31\">",
"     31",
"    </a>",
"    ]. However, there was no statin control arm to see whether patients might have tolerated rechallenge with a dose of statin able to achieve similar LDL-C reductions.",
"   </p>",
"   <p>",
"    Not all strains of red yeast rice are alike and results of these clinical trials may not generalize to different preparations. There is substantial variability across commercial preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. As an example, in a study that evaluated the content of twelve preparations of commercially available red yeast rice, the total monacolin content ranged from 0.31 to 11.15",
"    <span class=\"nowrap\">",
"     mg/capsule",
"    </span>",
"    and monacolin K (lovastatin) ranged from 0.10 to 10.09",
"    <span class=\"nowrap\">",
"     mg/capsule;",
"    </span>",
"    four of the preparations had elevated levels of citrinin, a potentially nephrotoxic mycotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/33\">",
"     33",
"    </a>",
"    ]. Furthermore, while short-term studies (up to four months) have found red yeast rice to be safe, no long-term studies have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, red yeast rice may have cholesterol lowering ability due to the presence of monacolins that have HMG CoA reductase inhibitor activity, and possibly other active substances. However, these extracts suffer from the same problem as many other natural products, that is, a lack of standardization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/34\">",
"     34",
"    </a>",
"    ]. This results in marked variability across brands in the content of the active ingredient and thus in efficacy in reducing LDL-C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Standardization'",
"    </a>",
"    .) Furthermore, long-term safety data are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GUGGULIPID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guggulipid is a preparation containing standardized guggul, an extract from the resin of the mukul myrrh tree that has been used as a treatment for hypercholesterolemia.",
"   </p>",
"   <p>",
"    However, a randomized, placebo-controlled trial in the United States involving 103 adults with hypercholesterolemia found that LDL levels",
"    <strong>",
"     increased",
"    </strong>",
"    significantly with three times daily guggulipid (1000 mg and 2000 mg) compared with placebo (+4 and +5 versus -5 percent); hypersensitivity rash occurred in 5 of 34 patients in the higher dose guggulipid arm and 1 of 33 patients in the lower dose arm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials in India have found that guggulipid decreased total cholesterol and LDL-C concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The authors of the US study suggested that possible explanations for the differing results between the Indian and US studies include differences in the populations' genetics, diet, and body fat composition. Additionally, though, methodologic concerns have been raised about both Indian studies. These include that one of the trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/36\">",
"     36",
"    </a>",
"    ] did not have a placebo arm. A further issue for the other Indian study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/37\">",
"     37",
"    </a>",
"    ] is that concerns have been raised about the accuracy of other papers published by these same authors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend the use of guggulipid for treatment of hypercholesterolemia until further efficacy and safety data are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POLICOSANOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Policosanol is a drug extracted from sugar cane wax. It contains a number of aliphatic alcohols. It appears to be well tolerated and some studies suggested that at doses of 10 to 20 mg daily it could reduce LDL-C concentrations by as much as 25 percent or more and could raise HDL-C by up to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a multicenter randomized trial in 143 patients found no evidence that policosanol, over a range of doses from 10 to 80 mg daily, was different from placebo in its effects on LDL-C, HDL-C, total cholesterol, triglycerides, or lipoprotein(a) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, there are only limited data on clinical endpoints. Also, there is variability in the available preparations such that the exact composition is uncertain, and the effective components and mechanism of action are relatively unknown.",
"   </p>",
"   <p>",
"    We do not recommend the use of policosanol for the treatment of hypercholesterolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GARLIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Garlic has been advocated as a method to lower serum cholesterol concentrations. There were conflicting data on efficacy from a number of small clinical trials and their meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/45-50\">",
"     45-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, a larger and well-performed randomized trial compared three different garlic preparations (raw, powdered, and aged garlic extracts at a daily dose approximately equivalent to one 4 gram clove) and placebo in 192 adults with LDL-C concentrations ranging from 130 to 190",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.36 to 4.91",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients were treated six days per week for six months, and none of the preparations of garlic had a significant effect on LDL-C or other lipid levels.",
"   </p>",
"   <p>",
"    We do not recommend garlic for the treatment of hypercholesterolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PLANT STEROLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plant sterols are similar in chemical structure to cholesterol, differing in their side chain configuration. The mechanism by which they lower cholesterol is thought to involve inhibition of cholesterol absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, the decrease in serum cholesterol is less than that expected by the degree of reduced absorption, likely because of a compensatory increase in hepatic cholesterol synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of products containing plant sterols are now available. A limitation on the development of such products is the poor water solubility of plant sterols. The most common solution is to esterify plant stanols or sterols with fatty acids to enhance availability in food fats such as margarines and salad dressings. Margarines intended for lowering cholesterol have been available longest and are the most studied.",
"   </p>",
"   <p>",
"    None of these products has been adequately studied for clinical endpoints [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/55\">",
"     55",
"    </a>",
"    ]. A study of dietary supplementation with plant sterols in mice found harmful vascular effects including impaired endothelial function and increased atherogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/56\">",
"     56",
"    </a>",
"    ]. Local accumulation of plant sterols has been observed in patients with aortic valve lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Margarines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesterol-lowering margarines enriched with plant sterols are available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/58\">",
"     58",
"    </a>",
"    ]. Plants contain a number of sterols. Two saturated plant stanols, sitostanol and campestanol, are the main sterols present in one of the products currently available in the United States, Benecol&reg;; sitosterol and campesterol are the major plant sterols found in the other product, Promise activ&trade; [formerly Take Control&reg;]. Daily intake of 0.8 to 3 g of plant stanols",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sterols in these margarines appears to lower serum cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/54\">",
"     54",
"    </a>",
"    ]. Responses to plant sterol ester containing spreads may vary by apoE genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have examined the efficacy of plant stanol- and sterol-enriched margarines for lowering cholesterol:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study randomly assigned 153 patients with mild hypercholesterolemia to consumption of margarine fortified with sitostanol or to unfortified margarine [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/54\">",
"       54",
"      </a>",
"      ]. Those consuming the fortified margarine had a 10 to 14 percent decrease in total and LDL-C that occurred predominantly in the first three months, although values continued to decline over the 12 months of the study. There was no significant difference in HDL-C and triglycerides between the two groups. Absorption of fat soluble vitamins did not appear to be affected, although serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      levels were significantly lowered. The participants could distinguish between the two margarines by taste, although could not decide which tasted better.",
"     </li>",
"     <li>",
"      A second study of sitostanol fortified margarine (3 g per day) in 22 postmenopausal women with coronary heart disease found that total and LDL-C were lowered by 13 and 20 percent compared to 5 percent in women consuming unfortified margarine [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/50\">",
"       50",
"      </a>",
"      ]. In a second group of 10 women on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , consumption of sitostanol fortified margarine for 12 weeks reduced the dose of simvastatin necessary to reach the target level of cholesterol.",
"     </li>",
"     <li>",
"      A third trial compared consumption of margarines supplemented with sitostanol (Benecol&reg;) to those with sterols from soybean, sheanut, or rice bran oil (mainly beta-sitosterol, campesterol, and stigmasterol), or to unfortified margarine in 100 patients with normal cholesterol or mild hypercholesterolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/60\">",
"       60",
"      </a>",
"      ]. The target amount of these margarines, 30 g per day, was achieved for most participants with total plant sterol or stanol intakes ranging from 1.7 to 3.2 g per day, largely due to variations in plant sterols in supplemented spreads. Sheanut and rice bran oil based margarines contained lower (around 48 percent) and different plant sterols when compared to the sitostanol and soybean oil products. Both soybean and sitostanol containing margarines lowered total and LDL-C by 8 to 13 percent compared with controls, without affecting HDL-C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stanol-enriched margarine can also reduce cholesterol in patients receiving a stable dose of a statin drug. As an example, one series of 167 subjects with an LDL-C &ge;130",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    despite at least three months of statin therapy, found that 5.1 g per day of plant stanol ester for eight weeks reduced total cholesterol by 12 percent (versus 5 percent for placebo) and LDL-C by 17 percent or 24",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (versus 7 percent and 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These short-term studies have shown no adverse effects of consumption of margarines fortified with plant",
"    <span class=\"nowrap\">",
"     sterols/stanol",
"    </span>",
"    esters. It is possible over the long-term that they can cause reduction in plasma concentrations of antioxidants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    and alpha tocopherol [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/54\">",
"     54",
"    </a>",
"    ]. Several studies have found only minimal impact of these margarines on circulating levels of fat-soluble vitamins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. Furthermore, another report suggested that consuming one additional serving per day of a high carotenoid vegetable or fruit counteracted any effects of the margarine in lowering plasma carotenoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/66\">",
"     66",
"    </a>",
"    ]. However, none of these studies were more than three weeks in duration.",
"   </p>",
"   <p>",
"    There have been no studies demonstrating that consumption of these stanol ester-containing margarines influences the incidence of coronary heart disease. Concerns related to the accumulation of plant sterols do not apply to these products since stanol esters are not absorbed, unlike plant sterols; they protect against the potential accumulation associated with beta-sitosterolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other products",
"    </span>",
"    &nbsp;&mdash;&nbsp;A method for increasing absorption of plant stanols without ingestion of fat-containing foods is to create an emulsification with lecithin which can then be formulated as a spray dried powder. This powder has been mixed with egg whites, lemonade drinks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/67\">",
"     67",
"    </a>",
"    ], and formulated into tablets containing 1.3 to 1.9 grams of plant stanols [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These products markedly reduce cholesterol absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/67\">",
"     67",
"    </a>",
"    ], and reduce total and LDL cholesterol concentrations to a similar degree to that seen with cholesterol-lowering margarines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the products currently available with lecithin emulsified plant stanols include Minute Maid&reg; Heart Wise&trade; orange juice, Rice Dream Heart Wise&trade; beverages, Silk&reg; Health Soymilk, and Trader Joe&rsquo;s Instant Oatmeal Heart Healthy Whole Grain.",
"   </p>",
"   <p>",
"    A study found that plant sterols combined with dark chocolate also reduced LDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;An advisory from the Nutrition Committee of the American Heart Association concluded that although foods containing plant",
"    <span class=\"nowrap\">",
"     sterols/stanol",
"    </span>",
"    esters are a promising addition to dietary intervention aimed at improving cardiac risk profiles, these products should not be used routinely by the general population until long-term studies are performed to ensure the absence of adverse effects; their use should be reserved for adults with hypercholesterolemia or an atherosclerotic event who require lowering of total and LDL-C levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/71\">",
"     71",
"    </a>",
"    ]. Although they can be used in hypercholesterolemic children, fat-soluble vitamin status should be monitored. It is uncertain if plant",
"    <span class=\"nowrap\">",
"     sterols/stanol",
"    </span>",
"    esters should be used in normocholesterolemic individuals who have risk factors for coronary artery disease, for example those with low HDL-C.",
"   </p>",
"   <p>",
"    Given the evidence that plant sterol supplementation may have harmful vascular effects in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/56\">",
"     56",
"    </a>",
"    ], and the lack of evidence of beneficial effects in humans, we suggest that patients not use these products until studies looking at clinical endpoints are available.",
"   </p>",
"   <p>",
"    Manufacturers recommend the following doses of plant",
"    <span class=\"nowrap\">",
"     sterol/stanol",
"    </span>",
"    esters fortified products:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Promise activ&trade; spread: Two tablespoons per day (1120 mg sitosterol per tablespoon [14 g] serving)",
"     </li>",
"     <li>",
"      Benecol&reg;: Three servings per day (1.5 g sitostanol per 1",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      teaspoon [8 g] serving)",
"     </li>",
"     <li>",
"      Minute Maid&reg; Heart Wise&trade; orange juice and Rice Dream Heart Wise&trade; beverages: Two 8 fluid ounce servings daily with meals (1 g plant sterols per 8 fluid ounces)",
"     </li>",
"     <li>",
"      Promise Activ&trade; SuperShots&trade;: One 3 fluid ounce serving daily (2 g plant sterols per 3 fluid ounces)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cost of fortified margarines is approximately two to five times that of ordinary margarine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/72\">",
"     72",
"    </a>",
"    ]. For a patient who wishes to take plant sterols, the choice of fortified food can reasonably be based on which would substitute for a food the patient already ingests (ie, a margarine user could substitute plant-sterol fortified margarine, etc.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POLYPHENOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyphenols are substances found primarily in plants, and foods made from plants such as tea, coffee, cocoa, olive oil, and red wine, that appear to have antioxidant effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. They also appear to have immunomodulatory and vasodilatory properties that could contribute to cardiovascular risk reduction. Polyphenols include flavonoids and flavonoid derivatives, lignans, phenolic acids, and stilbenes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study found an inverse association between mortality (total mortality as well as CHD mortality) and intake of flavanones and certain foods rich in flavonoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized crossover trial in 200 men compared the effects on serum lipids of virgin olive oil (high in polyphenols), refined olive oil (low in polyphenols), and a mixture of the two with intermediate polyphenol content [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/77\">",
"     77",
"    </a>",
"    ]. A dose-response was seen, where olive oil with higher amounts of polyphenols had greater effects in raising HDL-C and lowering oxidized LDL.",
"   </p>",
"   <p>",
"    The a priori hypothesis of the trial was that the phenolic content of olive oil would be related to its lipid benefits. While this study does appear to show that other components of olive oil, apart from monounsaturated fatty acids, affect lipid levels, it is uncertain whether it was actually the polyphenols that resulted in these differential benefits. There could be other important differences between virgin and refined olive oil.",
"   </p>",
"   <p>",
"    In addition to these lipid effects, a meta-analysis of randomized trials found consistent evidence that both acute and chronic chocolate and cocoa ingestion increase flow-mediated vasodilatation, reduce systolic and diastolic blood pressures, and reduce serum insulin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MARGARINES AND PRODUCTS LOW IN TRANS-FATTY ACIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some trans fatty acids occur naturally in foods, especially those of animal origin, although most trans unsaturated fatty acid consumption is a result of the industrial hydrogenation of polyunsaturated fatty acids, such as in vegetable oil [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/79\">",
"     79",
"    </a>",
"    ]. Numerous prepared foods such as cakes, cookies, commercially prepared fried foods, and some margarines may have a high content of trans unsaturated fatty acids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    .) Trans unsaturated acids can increase LDL-C and reduce HDL-C, while the consumption of foods that are low in trans unsaturated fatty acids (&lt;0.5 g per 100 g), such as soybean oil and semiliquid margarine, have beneficial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Inclusion of trans unsaturated fatty acids on food labels, as well as increasing the availability of trans fatty acid-free products, will aid in reducing current intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FIBER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limiting intakes of saturated and trans unsaturated fatty acids requires the substitution of other nutrients, unless there is a concomitant need to reduce energy intake as well. Substitution of carbohydrate leads to reduction in LDL-C, but in the absence of weight loss, extremely high proportion of carbohydrates (&gt;60 percent of energy) can elevate triglyceride levels and lower HDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Such changes are lessened with the incorporation of greater amounts of fiber, in which carbohydrate is derived from unprocessed whole foods [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain soluble fibers (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    , pectin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/54/16227?source=see_link\">",
"     wheat dextrin",
"    </a>",
"    , and oat products) will reduce LDL-C. In a meta-analysis, every gram increase in soluble fiber reduced LDL-C by an average of 2.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.057",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    this effect was similar with various soluble fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/85\">",
"     85",
"    </a>",
"    ]. The molecular weight and amount of beta-glucan in food products such as oats may alter the LDL-lowering effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/86\">",
"     86",
"    </a>",
"    ]. The addition of psyllium supplementation may result in small further reductions in LDL-C concentrations in patients receiving low dose statin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/87\">",
"     87",
"    </a>",
"    ]. The gel-forming attributes of dietary soluble fiber appear to account for its physiologic benefits including improved lipid profiles and glucose homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. A crossover study in 20 well-controlled diabetics found that compared to wheat bran, daily consumption of the ancient grain Salba (Salvia hispanica L.) reduced systolic blood pressure and levels of C-reactive protein and von Willebrand factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"     \"Patient information: High-fiber diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy that combines soluble fiber with plant sterols may also be of benefit. In a randomized crossover trial in adults with initial LDL-C concentrations between 100 and 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.59 and 4.14",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    four weeks of therapy with cookies that provided 2.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of plant sterols and 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    (7.7",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    soluble fiber) decreased LDL-C levels by 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/91\">",
"     91",
"    </a>",
"    ]. The therapy also decreased the number of HDL, LDL, and IDL (intermediate density lipoprotein) particles, with the decrease in HDL and LDL particles mainly in the small subfractions.",
"   </p>",
"   <p>",
"    In addition to effects on lipid levels, an observational study in a Mediterranean population at high cardiovascular risk found an association between increased fiber intake and decreased carotid intima-media thickness (CIMT) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III) and the American Heart Association recommend soluble fiber as an optional dietary strategy to reduce cholesterol levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/79,93\">",
"     79,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NUTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small randomized trials have shown that walnuts, which are rich in polyunsaturated fatty acids, have a beneficial effect on serum lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. As examples, one trial compared a Mediterranean diet to a diet in which walnuts replaced 35 percent of the energy obtained from monounsaturated fats [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/94\">",
"     94",
"    </a>",
"    ], and a second trial compared a National Cholesterol Education Program step 1 diet to a similar diet in which walnuts accounted for 20 percent of calories [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/95\">",
"     95",
"    </a>",
"    ]. The following respective benefits were noted with the walnut diets compared to the control diets: a 4 and 12 percent reduction in serum total cholesterol; and a 6 and 12 percent reduction in serum LDL-C.",
"   </p>",
"   <p>",
"    Other trials demonstrated similar lipid lowering effects with almonds and pistachios and other nuts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. An analysis that pooled individual patient data from 25 trials of nut consumption (including a number of nonrandomized trials) found that at a mean daily intake of 67 g of nuts, total cholesterol decreased by 10.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.28",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and LDL-C decreased by 10.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.26",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/99\">",
"     99",
"    </a>",
"    ]. A dose-response effect was seen and different types of nuts had similar effects on lipid levels.",
"   </p>",
"   <p>",
"    There is also evidence that increased nut intake is associated with improved cardiovascular outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review from the prospective Adventist Health Study, individuals who consumed nuts more than four times per week had significant reductions in mortality from coronary heart disease (relative risk 0.52) and in nonfatal infarctions (relative risk 0.49) compared to those who consumed nuts less than once per week [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a report from the Physicians' Health Study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/101\">",
"       101",
"      </a>",
"      ]. After controlling for known cardiac risk factors and other dietary habits, men who consumed nuts two or more times per week had, when compared to men who rarely or never consumed nuts, significant reductions in total coronary deaths and sudden cardiac deaths (relative risk 0.53 and 0.70, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2011 meta-analysis of 14 randomized trials found that consumption of green tea beverages and extracts results in a statistically significant reduction in LDL-C (-2.19",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [-0.057",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    but no statistically significant change in HDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/102\">",
"     102",
"    </a>",
"    ]. This small reduction in LDL-C is unlikely to be clinically important.",
"   </p>",
"   <p>",
"    Although not specifically related to lipid levels, an observational study from Japan found that consumption of green tea was inversely associated with all-cause mortality and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CALCIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human and animal studies have suggested that calcium intake may affect the serum lipid concentration by binding to fatty acids and bile acids in the gut, thereby interfering with lipid absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. In addition, at least two randomized, controlled trials have found that calcium supplementation causes potentially beneficial changes in circulating lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/106,107\">",
"     106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one study randomly assigned 223 postmenopausal women, who were not receiving therapy for hyperlipidemia or osteoporosis, to receive calcium (1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/107\">",
"     107",
"    </a>",
"    ]. After 12 months, the HDL-C concentration and HDL to LDL-C ratio had increased significantly more in the calcium than cholesterol group (change from baseline for HDL 4.64 versus 1.16",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.12 versus 0.03",
"    <span class=\"nowrap\">",
"     mmol/L];",
"    </span>",
"    change in ratio 0.07 versus 0.02).",
"   </p>",
"   <p>",
"    However, beneficial effects on serum lipids were not noted in another randomized trial of 193 men and women ages 30 to 74 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/108\">",
"     108",
"    </a>",
"    ]. The cause for the discrepant findings is uncertain but may be related to differences in the patient populations that were studied.",
"   </p>",
"   <p>",
"    There is considerable controversy around the effects of calcium supplementation on the risk of cardiovascular disease. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link&amp;anchor=H13#H13\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179025594\">",
"    <span class=\"h1\">",
"     SELENIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have found an association between increased",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    and elevations in total and LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/109,110\">",
"     109,110",
"    </a>",
"    ], and perhaps also elevations in HDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/109,111\">",
"     109,111",
"    </a>",
"    ]. A randomized trial of supplementation with high-selenium yeast found small reductions in total cholesterol levels that did not seem to show a dose response effect, minimal changes in HDL-C compared with placebo, and small increases in the ratio of total cholesterol to HDL-C that were smaller than the increases seen with placebo and appeared to show a dose response (less increase in ratio with higher doses of selenium) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/112\">",
"     112",
"    </a>",
"    ]. Overall, the results from this randomized trial suggest little benefit on lipids with selenium supplementation, but also do not suggest worsening of lipid profiles with selenium.",
"   </p>",
"   <p>",
"    Randomized trials have not found a beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    supplementation on cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. As such, selenium supplementation is not recommended to improve lipids or cardiovascular health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMBINATION DIET",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Multiple components",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diet that includes diverse cholesterol-lowering components may be particularly effective in lowering lipid levels. A study that compared a diet very low in saturated fat, a diet very low in saturated fat plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and a diverse diet high in plant sterols (1",
"    <span class=\"nowrap\">",
"     g/1000",
"    </span>",
"    kcal), soy protein (21.4",
"    <span class=\"nowrap\">",
"     g/1000",
"    </span>",
"    kcal), viscous fibers (9.8",
"    <span class=\"nowrap\">",
"     g/1000",
"    </span>",
"    kcal), and almonds (14",
"    <span class=\"nowrap\">",
"     g/1000",
"    </span>",
"    kcal) found reductions in LDL-C concentration over a one month period of 8.0, 30.9, and 28.6 percent respectively; there was no statistically significant difference between the group receiving statin therapy and the group receiving the diverse diet [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/115\">",
"     115",
"    </a>",
"    ]. A subsequent trial from the same group found that at six months of therapy the diverse diet (with more or less intense counseling in the diet) led to greater reductions in LDL-C than a low saturated fat diet (13.8 and 13.1 percent versus 3.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial comparing three healthy diets found that partial substitution of carbohydrate with either protein or monounsaturated fat can improve lipid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mediterranean diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Mediterranean diet appears to reduce the risk of cardiovascular events. There is no single Mediterranean diet, but such diets are typically high in fruits, vegetables, whole grains, beans, nuts, and seeds and include olive oil as an important source of fat; there are typically low to moderate amounts of fish, poultry, and dairy products, and there is little red meat. It is uncertain whether the cardiovascular benefits of a Mediterranean diet are due to its lipid effects. &nbsp;",
"   </p>",
"   <p>",
"    A 2011 meta-analysis of six randomized trials (N = 2650) comparing Mediterranean to low fat diets in",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    individuals found that Mediterranean diet led to a greater reduction in total cholesterol (-7.4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    95% CI -10.3 to -4.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [-0.19",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    CI -0.27 to -0.11",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and a statistically nonsignificant greater reduction in LDL-C (-3.3",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    CI -7.3 to +0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [-0.09",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    CI -0.19 to +0.02",
"    <span class=\"nowrap\">",
"     mmol/L]);",
"    </span>",
"    HDL-C was not significantly different between the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Mediterranean diet also appears to affect clinical outcomes. In prospective cohorts of older adults in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/119,120\">",
"     119,120",
"    </a>",
"    ] and in American men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/121,122\">",
"     121,122",
"    </a>",
"    ], this dietary pattern along with other lifestyle changes has been associated with marked reductions in mortality from cardiovascular disease. In a report from the Seguimiento Universidad de Navarra (SUN) cohort, after 74 months this dietary pattern was inversely associated with incidence of metabolic syndrome (odds ratio 0.20) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/123,124\">",
"     123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial in patients who had had a myocardial infarction found fewer subsequent cardiac events among those assigned to a Mediterranean diet [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/125\">",
"     125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Lifestyle modification'",
"    </a>",
"    .) These results may in part be related to greater reductions in inflammatory markers and insulin resistance in patients eating a Mediterranean diet [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. A Mediterranean diet may also decrease LDL oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large randomized trial (N = 7447) compared three diets in patients at high cardiovascular risk: a Mediterranean diet supplemented with olive oil, a Mediterranean diet supplemented with mixed nuts, and advice to reduce dietary fat [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/129\">",
"     129",
"    </a>",
"    ]. The trial was stopped early after a median follow-up of 4.8 years. For the primary composite cardiovascular endpoint of myocardial infarction, stroke, and cardiovascular death, event rates were similar for the Mediterranean diets supplemented with olive oil and mixed nuts, and lower than for the control diet (8.1 and 8.0 events per 1000 person-years respectively, versus 11.2 events per 1000 person-years; HR for both Mediterranean diets combined 0.71, 95% CI 0.56-0.90). Although this trial suggests possible substantial cardiovascular benefits from a Mediterranean diet, there was a surprisingly large reduction in events, a low total number of events (288), and the trial was stopped early for benefit. This raises concerns that the apparent benefits of a Mediterranean diet could have been overestimated, since this can be a problem in trials that are stopped early for benefit, particularly when there are also relatively few events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/130-132\">",
"     130-132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for such a dietary pattern (high intakes of vegetables, fruit, legumes, whole grains, and fish) comes from a cohort study of 24,444 postmenopausal women where such a pattern, along with three other low-risk lifestyle behaviors, was associated with a 92 percent decreased risk of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/133\">",
"     133",
"    </a>",
"    ]. Even in patients with an acute coronary syndrome, adherence to a Mediterranean diet is associated with better prognosis and greater preservation of left ventricular systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diets that are identical in major nutrient categories but differ in fiber content may have different effects on lipids, especially when body weight is held relatively constant. A four-week randomized trial that compared two diets identical in total fat, saturated fat, protein, carbohydrate, and cholesterol content in 120 adults found that, compared with a typical US low-fat diet, a diet that used more vegetables, legumes, and whole grains to achieve this content led to significantly greater reductions in total and LDL cholesterol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/135\">",
"     135",
"    </a>",
"    ]. The second diet contained more than twice the amount of fiber (both soluble and insoluble components).",
"   </p>",
"   <p>",
"    Even the simple behavior of regular consumption of whole grain breakfast cereal is associated with a decreased risk of heart failure. Among 21,376 participants of the Physicians Health Study, consumption of seven or more servings weekly of such cereal was associated with a 29 percent decrease in risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     DASH diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Dietary Approaches to Stop Hypertension (DASH) diet is rich in fruits and vegetables, moderate in low-fat dairy products, low in animal protein, and contains many plant sources of protein including legumes and nuts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/137\">",
"     137",
"    </a>",
"    ]. This diet reduces blood pressure (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link&amp;anchor=H4#H4\">",
"     \"Diet in the treatment and prevention of hypertension\", section on 'DASH trial'",
"    </a>",
"    ). The DASH diet decreases LDL-C and has been shown to improve several lipid markers in type 2 diabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/138,139\">",
"     138,139",
"    </a>",
"    ]. It may also decrease the risk of stroke and CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/51/28474/abstract/140,141\">",
"     140,141",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"     \"Patient information: Low sodium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"       \"Patient information: Diet and health (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/56/24450?source=see_link\">",
"       \"Patient information: Can foods or supplements lower cholesterol? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       \"Patient information: Diet and health (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"       \"Patient information: High-fiber diet (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"       \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21537837\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of dietary approaches and dietary supplements can affect lipid levels. There are limited or no data, however, for most such interventions with regard to clinical endpoints, and not all interventions that improve patient lipid profiles improve patient outcomes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H11#H11\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Use of medications other than statins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supplementation with fish oil may have cardiac benefits unrelated to lipid effects and is also part of the management of refractory hypertriglyceridemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fish oil and omega-3 fatty acids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H3#H3\">",
"       \"Fish oil and marine omega-3 fatty acids\", section on 'Effects on cardiovascular risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H301630#H301630\">",
"       \"Approach to the patient with hypertriglyceridemia\", section on 'Fish oil'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Red yeast rice contains naturally-occurring substances that have HMG CoA reductase inhibitor activity. These reduce LDL-C and could be expected to have effects on cardiovascular endpoints. However, there is a lack of standardization of red yeast rice supplements and, at least in the United States, there is marked variability across brands in the content of the active ingredient. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Red yeast rice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plant sterols are similar in chemical structure to cholesterol, differing in their side chain configuration. A number of plant sterol supplements are sold as widely-promoted commercial products, including margarines, juices, and powders. Although plant sterols reduce LDL-C, they have not been evaluated for effects on clinical endpoints in humans and there has been some evidence for harmful vascular effects in mouse models. As such, we suggest that patients not use these products until studies looking at clinical endpoints are available. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Plant sterols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A Mediterranean diet appears to reduce the risk of cardiovascular events. There is no single Mediterranean diet, but such diets are typically high in fruits, vegetables, whole grains, beans, nuts, and seeds and include olive oil as an important source of fat; there are typically low to moderate amounts of fish, poultry, and dairy products, and there is little red meat. It is uncertain whether the cardiovascular benefits of a Mediterranean diet are due to its lipid effects. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mediterranean diet'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/1\">",
"      Vogel JH, Bolling SF, Costello RB, et al. Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). J Am Coll Cardiol 2005; 46:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/2\">",
"      Varady KA, Jones PJ. Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels? J Nutr 2005; 135:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/3\">",
"      Rissanen T, Voutilainen S, Nyyss&ouml;nen K, et al. Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. Circulation 2000; 102:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/4\">",
"      Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001; 161:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/5\">",
"      Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/6\">",
"      Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984; 74:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/7\">",
"      Harris WS, Connor WE, Illingworth DR, et al. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res 1990; 31:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/8\">",
"      Sullivan DR, Sanders TA, Trayner IM, Thompson GR. Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis 1986; 61:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/9\">",
"      Abbey M, Clifton P, Kestin M, et al. Effect of fish oil on lipoproteins, lecithin:cholesterol acyltransferase, and lipid transfer protein activity in humans. Arteriosclerosis 1990; 10:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/10\">",
"      Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/11\">",
"      Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993; 13:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/12\">",
"      Suzukawa M, Abbey M, Howe PR, Nestel PJ. Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 1995; 36:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/13\">",
"      Patti L, Maffettone A, Iovine C, et al. Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 1999; 146:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/14\">",
"      Pan A, Yu D, Demark-Wahnefried W, et al. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr 2009; 90:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/15\">",
"      Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol 2000; 35:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/16\">",
"      Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/17\">",
"      Crouse JR 3rd, Morgan T, Terry JG, et al. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999; 159:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/18\">",
"      Teixeira SR, Potter SM, Weigel R, et al. Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr 2000; 71:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/19\">",
"      Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006; 113:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/20\">",
"      Figtree GA, Griffiths H, Lu YQ, et al. Plant-derived estrogens relax coronary arteries in vitro by a calcium antagonistic mechanism. J Am Coll Cardiol 2000; 35:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/21\">",
"      Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997; 17:3392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/22\">",
"      Walker HA, Dean TS, Sanders TA, et al. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol. Circulation 2001; 103:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/23\">",
"      Teede HJ, McGrath BP, DeSilva L, et al. Isoflavones reduce arterial stiffness: a placebo-controlled study in men and postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/24\">",
"      Squadrito F, Altavilla D, Crisafulli A, et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med 2003; 114:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/25\">",
"      Chan YH, Lau KK, Yiu KH, et al. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr 2007; 86:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/26\">",
"      Teede HJ, Dalais FS, Kotsopoulos D, et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 2001; 86:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/27\">",
"      Li, CL, Zhu, Y, Wang, Y, et al. Monascus purpureus-fermented rice (red yeast rice): a natural food product that lowers blood cholesterol in animal models of hypercholesterolemia. Nutr Res 1998; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/28\">",
"      Patrick L, Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev 2001; 6:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/29\">",
"      Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999; 69:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/30\">",
"      Wang, J, Lu, Z, Chi, J, et al. Multicenter clinical trial of the serum lipid lowering effects of Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Cur Ther Res 1997; 58:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/31\">",
"      Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009; 150:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/32\">",
"      Heber D, Lembertas A, Lu QY, et al. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/33\">",
"      Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010; 170:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/34\">",
"      Red yeast rice. Med Lett Drugs Ther 2009; 51:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/35\">",
"      Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003; 290:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/36\">",
"      Nityanand S, Srivastava JS, Asthana OP. Clinical trials with gugulipid. A new hypolipidaemic agent. J Assoc Physicians India 1989; 37:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/37\">",
"      Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994; 8:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/38\">",
"      Soman CR. Indo-Mediterranean diet and progression of coronary artery disease. Lancet 2005; 366:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/39\">",
"      Mann J. The Indo-Mediterranean diet revisited. Lancet 2005; 366:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/40\">",
"      Horton R. Expression of concern: Indo-Mediterranean Diet Heart Study. Lancet 2005; 366:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/41\">",
"      White C. Suspected research fraud: difficulties of getting at the truth. BMJ 2005; 331:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/42\">",
"      Chen JT, Wesley R, Shamburek RD, et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005; 25:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/43\">",
"      Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002; 143:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/44\">",
"      Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006; 295:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/45\">",
"      Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial. Arch Intern Med 1998; 158:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/46\">",
"      Superko HR, Krauss RM. Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein(a). J Am Coll Cardiol 2000; 35:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/47\">",
"      Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. Am J Clin Nutr 1997; 65:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/48\">",
"      Steiner M, Khan AH, Holbert D, Lin RI. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr 1996; 64:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/49\">",
"      Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993; 119:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/50\">",
"      Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 1997; 96:4226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/51\">",
"      Gardner CD, Lawson LD, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med 2007; 167:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/52\">",
"      Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. Am J Clin Nutr 1986; 43:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/53\">",
"      Jones PJ, MacDougall DE, Ntanios F, Vanstone CA. Dietary phytosterols as cholesterol-lowering agents in humans. Can J Physiol Pharmacol 1997; 75:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/54\">",
"      Miettinen TA, Puska P, Gylling H, et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995; 333:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/55\">",
"      Weing&auml;rtner O, B&ouml;hm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J 2009; 30:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/56\">",
"      Weing&auml;rtner O, L&uuml;tjohann D, Ji S, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol 2008; 51:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/57\">",
"      Helske S, Miettinen T, Gylling H, et al. Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves. J Lipid Res 2008; 49:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/58\">",
"      Katan MB, Grundy SM, Jones P, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003; 78:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/59\">",
"      Sanchez-Muniz FJ, Maki KC, Schaefer EJ, Ordovas JM. Serum lipid and antioxidant responses in hypercholesterolemic men and women receiving plant sterol esters vary by apolipoprotein E genotype. J Nutr 2009; 139:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/60\">",
"      Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 1998; 52:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/61\">",
"      Blair SN, Capuzzi DM, Gottlieb SO, et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000; 86:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/62\">",
"      Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Am J Clin Nutr 1999; 69:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/63\">",
"      Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Jones PJ. No changes in serum fat-soluble vitamin and carotenoid concentrations with the intake of plant sterol/stanol esters in the context of a controlled diet. Metabolism 2002; 51:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/64\">",
"      Mensink RP, Ebbing S, Lindhout M, et al. Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations. Atherosclerosis 2002; 160:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/65\">",
"      Mussner MJ, Parhofer KG, Von Bergmann K, et al. Effects of phytosterol ester-enriched margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to basal cholesterol and fat intake. Metabolism 2002; 51:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/66\">",
"      Noakes M, Clifton P, Ntanios F, et al. An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations. Am J Clin Nutr 2002; 75:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/67\">",
"      Spilburg CA, Goldberg AC, McGill JB, et al. Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. J Am Diet Assoc 2003; 103:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/68\">",
"      McPherson TB, Ostlund RE, Goldberg AC, et al. Phytostanol tablets reduce human LDL-cholesterol. J Pharm Pharmacol 2005; 57:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/69\">",
"      Goldberg AC, Ostlund RE Jr, Bateman JH, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol 2006; 97:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/70\">",
"      Allen RR, Carson L, Kwik-Uribe C, et al. Daily consumption of a dark chocolate containing flavanols and added sterol esters affects cardiovascular risk factors in a normotensive population with elevated cholesterol. J Nutr 2008; 138:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/71\">",
"      Lichtenstein AH, Deckelbaum RJ. AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 2001; 103:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/72\">",
"      Cholesterol-lowering margarines. Med Lett Drugs Ther 1999; 41:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/73\">",
"      Zern TL, Fernandez ML. Cardioprotective effects of dietary polyphenols. J Nutr 2005; 135:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/74\">",
"      Hollman PC, Cassidy A, Comte B, et al. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr 2011; 141:989S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/75\">",
"      Tangney CC, Rasmussen HE. Polyphenols, inflammation, and cardiovascular disease. Curr Atheroscler Rep 2013; 15:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/76\">",
"      Mink PJ, Scrafford CG, Barraj LM, et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007; 85:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/77\">",
"      Covas MI, Nyyss&ouml;nen K, Poulsen HE, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med 2006; 145:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/78\">",
"      Hooper L, Kay C, Abdelhamid A, et al. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr 2012; 95:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/79\">",
"      American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/80\">",
"      Judd JT, Clevidence BA, Muesing RA, et al. Dietary trans fatty acids: effects on plasma lipids and lipoproteins of healthy men and women. Am J Clin Nutr 1994; 59:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/81\">",
"      Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 1999; 340:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/82\">",
"      Dreon DM, Fernstrom HA, Miller B, Krauss RM. Low-density lipoprotein subclass patterns and lipoprotein response to a reduced-fat diet in men. FASEB J 1994; 8:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/83\">",
"      Starc TJ, Shea S, Cohn LC, et al. Greater dietary intake of simple carbohydrate is associated with lower concentrations of high-density-lipoprotein cholesterol in hypercholesterolemic children. Am J Clin Nutr 1998; 67:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/84\">",
"      Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000; 71:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/85\">",
"      Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999; 69:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/86\">",
"      Wolever TM, Tosh SM, Gibbs AL, et al. Physicochemical properties of oat &beta;-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. Am J Clin Nutr 2010; 92:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/87\">",
"      Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med 2005; 165:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/88\">",
"      Fernandez ML. Soluble fiber and nondigestible carbohydrate effects on plasma lipids and cardiovascular risk. Curr Opin Lipidol 2001; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/89\">",
"      Roy S, Vega-Lopez S, Fernandez ML. Gender and hormonal status affect the hypolipidemic mechanisms of dietary soluble fiber in guinea pigs. J Nutr 2000; 130:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/90\">",
"      Vuksan V, Whitham D, Sievenpiper JL, et al. Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial. Diabetes Care 2007; 30:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/91\">",
"      Shrestha S, Volek JS, Udani J, et al. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr 2006; 136:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/92\">",
"      Buil-Cosiales P, Irimia P, Ros E, et al. Dietary fibre intake is inversely associated with carotid intima-media thickness: a cross-sectional assessment in the PREDIMED study. Eur J Clin Nutr 2009; 63:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/93\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/94\">",
"      Zamb&oacute;n D, Sabat&eacute; J, Mu&ntilde;oz S, et al. Substituting walnuts for monounsaturated fat improves the serum lipid profile of hypercholesterolemic men and women. A randomized crossover trial. Ann Intern Med 2000; 132:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/95\">",
"      Sabat&eacute; J, Fraser GE, Burke K, et al. Effects of walnuts on serum lipid levels and blood pressure in normal men. N Engl J Med 1993; 328:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/96\">",
"      Ros E, N&uacute;&ntilde;ez I, P&eacute;rez-Heras A, et al. A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial. Circulation 2004; 109:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/97\">",
"      Sabat&eacute; J, Haddad E, Tanzman JS, et al. Serum lipid response to the graduated enrichment of a Step I diet with almonds: a randomized feeding trial. Am J Clin Nutr 2003; 77:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/98\">",
"      Gebauer SK, West SG, Kay CD, et al. Effects of pistachios on cardiovascular disease risk factors and potential mechanisms of action: a dose-response study. Am J Clin Nutr 2008; 88:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/99\">",
"      Sabat&eacute; J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. Arch Intern Med 2010; 170:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/100\">",
"      Fraser GE, Sabat&eacute; J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of coronary heart disease. The Adventist Health Study. Arch Intern Med 1992; 152:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/101\">",
"      Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. Arch Intern Med 2002; 162:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/102\">",
"      Zheng XX, Xu YL, Li SH, et al. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr 2011; 94:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/103\">",
"      Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/104\">",
"      Govers MJ, Van der Meet R. Effects of dietary calcium and phosphate on the intestinal interactions between calcium, phosphate, fatty acids, and bile acids. Gut 1993; 34:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/105\">",
"      Denke MA, Fox MM, Schulte MC. Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. J Nutr 1993; 123:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/106\">",
"      Bell L, Halstenson CE, Halstenson CJ, et al. Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med 1992; 152:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/107\">",
"      Reid IR, Mason B, Horne A, et al. Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. Am J Med 2002; 112:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/108\">",
"      Bostick RM, Fosdick L, Grandits GA, et al. Effect of calcium supplementation on serum cholesterol and blood pressure. A randomized, double-blind, placebo-controlled, clinical trial. Arch Fam Med 2000; 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/109\">",
"      Laclaustra M, Stranges S, Navas-Acien A, et al. Serum selenium and serum lipids in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Atherosclerosis 2010; 210:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/110\">",
"      Stranges S, Laclaustra M, Ji C, et al. Higher selenium status is associated with adverse blood lipid profile in British adults. J Nutr 2010; 140:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/111\">",
"      Salonen JT, Salonen R, Sepp&auml;nen K, et al. Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men. Atherosclerosis 1988; 70:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/112\">",
"      Rayman MP, Stranges S, Griffin BA, et al. Effect of supplementation with high-selenium yeast on plasma lipids: a randomized trial. Ann Intern Med 2011; 154:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/113\">",
"      Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; 3:CD007176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/114\">",
"      Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/115\">",
"      Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/116\">",
"      Jenkins DJ, Jones PJ, Lamarche B, et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA 2011; 306:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/117\">",
"      Appel LJ, Sacks FM, Carey VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005; 294:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/118\">",
"      Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 2011; 124:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/119\">",
"      Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/120\">",
"      Mart&iacute;nez-Gonz&aacute;lez MA, Garc&iacute;a-L&oacute;pez M, Bes-Rastrollo M, et al. Mediterranean diet and the incidence of cardiovascular disease: a Spanish cohort. Nutr Metab Cardiovasc Dis 2011; 21:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/121\">",
"      King DE, Mainous AG 3rd, Geesey ME. Turning back the clock: adopting a healthy lifestyle in middle age. Am J Med 2007; 120:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/122\">",
"      Fung TT, Rexrode KM, Mantzoros CS, et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 2009; 119:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/123\">",
"      Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, et al. Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care 2007; 30:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/124\">",
"      Paletas K, Athanasiadou E, Sarigianni M, et al. The protective role of the Mediterranean diet on the prevalence of metabolic syndrome in a population of Greek obese subjects. J Am Coll Nutr 2010; 29:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/125\">",
"      De Lorgeril M, Salen P, Martin JL, et al. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 1996; 28:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/126\">",
"      Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/127\">",
"      Estruch R, Mart&iacute;nez-Gonz&aacute;lez MA, Corella D, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006; 145:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/128\">",
"      Fit&oacute; M, Guxens M, Corella D, et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med 2007; 167:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/129\">",
"      Estruch R, Ros E, Salas-Salvad&oacute; J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/130\">",
"      Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/131\">",
"      Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/132\">",
"      Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol 2011; 64:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/133\">",
"      Akesson A, Weismayer C, Newby PK, Wolk A. Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myocardial infarction in women. Arch Intern Med 2007; 167:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/134\">",
"      Chrysohoou C, Panagiotakos DB, Aggelopoulos P, et al. The Mediterranean diet contributes to the preservation of left ventricular systolic function and to the long-term favorable prognosis of patients who have had an acute coronary event. Am J Clin Nutr 2010; 92:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/135\">",
"      Gardner CD, Coulston A, Chatterjee L, et al. The effect of a plant-based diet on plasma lipids in hypercholesterolemic adults: a randomized trial. Ann Intern Med 2005; 142:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/136\">",
"      Djouss&eacute; L, Gaziano JM. Breakfast cereals and risk of heart failure in the physicians' health study I. Arch Intern Med 2007; 167:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/137\">",
"      Champagne CM. Dietary interventions on blood pressure: the Dietary Approaches to Stop Hypertension (DASH) trials. Nutr Rev 2006; 64:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/138\">",
"      Obarzanek E, Sacks FM, Vollmer WM, et al. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 2001; 74:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/139\">",
"      Azadbakht L, Fard NR, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care 2011; 34:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/140\">",
"      Fung TT, Chiuve SE, McCullough ML, et al. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008; 168:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/51/28474/abstract/141\">",
"      Chen ST, Maruthur NM, Appel LJ. The effect of dietary patterns on estimated coronary heart disease risk: results from the Dietary Approaches to Stop Hypertension (DASH) trial. Circ Cardiovasc Qual Outcomes 2010; 3:484.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4561 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28474=[""].join("\n");
var outline_f27_51_28474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21537837\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FISH OIL AND OMEGA-3 FATTY ACIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SOY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RED YEAST RICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GUGGULIPID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POLICOSANOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GARLIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PLANT STEROLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Margarines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POLYPHENOLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MARGARINES AND PRODUCTS LOW IN TRANS-FATTY ACIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FIBER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NUTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CALCIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179025594\">",
"      SELENIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMBINATION DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Multiple components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mediterranean diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DASH diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21537837\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/56/24450?source=related_link\">",
"      Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_51_28475="Skin diseases in RPC";
var content_f27_51_28475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cutaneous manifestations in 645 patients with relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Actinic granuloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alopecia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angioedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aphthous lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis herpetiformis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidermolysis bullosa acquisita",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema annulare centrifugum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema multiforme",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema elevatum diutinum granuloma annulare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized normolipemic plane xanthomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperpigmentation at sites of cartilage involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaposi sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratodermia blennorrhagicum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytoclastic vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Livedo reticularis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyoderma gangrenosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweet's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weber-Christian disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28475=[""].join("\n");
var outline_f27_51_28475=null;
var title_f27_51_28476="Biologic agents in IBD";
var content_f27_51_28476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biological agents associated with inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Growth factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Transforming growth factor beta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Platelet-activating factor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Keratinocyte growth factor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trefoil peptides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inflammatory cytokines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-1 receptor antagonist",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            TNF-alpha",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IFN-gamma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neuropeptides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Substance P",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Reactive oxygen metabolites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitric oxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Arachidonic acid metabolites",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Immunoregulatory cytokines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-2",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-4",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-6",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-12",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Chemokines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            MCP-1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            IL-8",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cell adhesion molecules",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            ICAM-1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Short chain fatty acids",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28476=[""].join("\n");
var outline_f27_51_28476=null;
var title_f27_51_28477="Prevalence of BPH with age";
var content_f27_51_28477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prevalence of benign prostatic hyperplasia pathology with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age-associated increase in pathologic evidence of benign prostatic hyperplasia in 1075 men at autopsy. The percentage with benign prostatic hyperplasia was determined during 10-year intervals from five different studies; the mean values are shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Berry, SJ, Coffey, DS, Walsh, PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28477=[""].join("\n");
var outline_f27_51_28477=null;
var title_f27_51_28478="Heel spur";
var content_f27_51_28478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heel spur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain film of the calcaneus bone demonstrates enlargement with inflammation around a spur at the insertion of the plantar aponeurosis inferior to the calcaneus bone (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28478=[""].join("\n");
var outline_f27_51_28478=null;
var title_f27_51_28479="Vitreous hemorrhage";
var content_f27_51_28479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitreous hemorrhage: Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color fundus photograph displaying vitreous hemorrhage arising from neovascularization at the disc (NVD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_51_28479=[""].join("\n");
var outline_f27_51_28479=null;
